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Untersuchung der Antikörper Antwort und Nasenausscheidung nach EHV-1/4 Impfung und 





Im Teil A wurden die Antikörperkinetik und Virusausscheidung nach Impfung mit einer 
inaktivierten EHV-1/4 Vakzine untersucht. Von 20 Pferden wurden 15 geimpft, wobei 5 
Kontrollpferde ohne Impfung belassen wurden. Serumproben wurden vor jeder Impfung und 
monatlich während eines Jahres mittels ELISA analysiert. Nasentupfer wurden vor jeder 
Impfung und an den 5 folgenden Tagen mittels Real-Time PCR untersucht. 
Alle Pferde waren zu jedem Zeitpunkt positiv für EHV-4. Von l5 geimpften Pferden waren 8 
mindestens zu einem Messzeitpunkt und 5 über mehrere Monate EHV-1 seropositiv. Ein 
EHV-1 induzierter Abort ereignete sich im Stall der Kontrollgruppe, wobei 4/5 Pferde an 
mindestens einem Messzeitpunkt EHV-1 seropositiv waren. EHV-l/4 Virusausscheidung im 
Nasensekret kam nach allen Impfungen vor, am häufigsten jedoch nach der letzten Impfung 
im Winter. 
Die humorale Immunantwort insbesondere gegen die EHV-1 Komponente der Vakzine fällt 
individuell und moderat aus. Die erhöhte EHV-1/4 Virusausscheidung nach der Winter 
Impfung könnte saisonal begründet sein. 
Im Teil B wurde die Prävalenz von equinen Herpesviren (EHV) im Nasensekret von 68 
zufällig ausgewählten Proben aus der Schweizer Pferdepopulation mittels Panherpes nested 
PCR untersucht. Von 68 Proben waren 40 positiv für ein EHV, wovon 26 auf EHV-2, 8 auf 
EHV-5 und 6 auf AHV-5 getestet wurden. 
Wie erwartet ist die EHV-2 Virusausscheidung im Nasensekret gesunder Pferde in der 
Schweiz häufig, wobei EHV-5 und AHV-5 selten detektiert wurden. 
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In Part A of this study, the antibody kinetics and equine herpesvirus (EHV) shedding 
following vaccination with a combined inactive whole virus vaccine were assessed. Fifteen 
horses were vaccinated, 5 control horses remained unvaccinated. Blood samples taken before 
every vaccination and monthly for one year were analyzed with an ELISA. Nasal swabs 
collected from every horse before vaccination and daily for 5 days were analyzed using real-
time PCR. 
All horses were seropositive for EHV-4 at every timepoint. Eight of fifteen vaccinated horses 
were seropositive for EHV-1 at least at one sampling timepoint, 5/15 displayed a sustained 
high antibody concentration over several months. EHV-1 abortion occurred in the barn of the 
control group, 4/5horses were seropositive for EHV-1 at least one sampling timepoint. EHV-
1/l4 viral shedding after vaccination occurred occasionally with the highest frequency after 
the last administered vaccination in winter. 
An individual but moderate humoral immune response is suggested. A seasonal component of 
EHV shedding is indicated. 
In Part B of the study, the prevalence of EHV in nasal secretion of 68 randomized selected 
samples of the Swiss horse population were analyzed by panherpes nested PCR. Fourty of 
sixty-eight nasal swabs were tested positive for EHV, 26 for EHV-2,8 for EHV-5 and 6 for 
AHV-5. 
As expected, EHV-2 viral shedding in healthy horses of Switzerland is common, whereby 
EHV-5 and AHV-5 is rarely detected in the investigated population. 
 





AAEP   American Association of Equine Practitioners 
AHV   Asinine herpesvirus 
BI   Basic immunization 
BMCF  bovine malignant catarrhal fever 
BoHV-1  Bovine herpesvirus 1 
CF   Complement-fixing 
CFT   Complement-fixing test 
CG   chorionic gonadotropin 
CNS   Central Nervous System 
CPE   cytopathic effect 
CT   cycle treshold 
CTL   cytotoxic T lymphocytes 
DEPC   Diethylpyrocarbonate treated water 
DNA   Desoxyribonucleic acid 
EHM   Equine herpes myeloencephalopathy 
EHV   Equine herpesvirus 
EHV-1 D752  neuropathogenic EHV-1 strain 
EHV-1 N752  non – neuropathogenic EHV-1 strain 
ELISA  Enzyme linked immunosorbent assay  
EMPF   Equine multinodular pulmonary fibrosis 
GHV   Gazelle herpesvirus 
gB   glycoprotein B 
gG   glycoprotein G 
gH   glycoprotein G 
gp   glycoprotein 
hpi   hours post infection 
HSV   herpes simplex virus 
ISCOM  Immune stimulating complexes 
IWVV   inactivated whole virus vaccine  
MHC-1  major histocompatibility complex 1 
MLV   modified live vaccine 
nip   non-interpretable 
nt   nucleotid 
OD   optical density 
ORFS   open reading frames 
PBL   Peripheral blood lymphocytes 
PBMC  Peripheral blood mononuclear cells 
RFLP    restriction fragment length polymorphism 
PRV   pseudorabies virus 
SLN   submandibular lymph nodes 
SN   serum neutralizing 
URT   upper respiratory tract 
VN   virus neutralizing 






The order of Herpesvirales contains three families, three subfamilies, 17 generas and 90 
species. A wide range of animals can be infected, including mammals, reptiles, birds, fish, 
frogs and even non-vertebrae.1 The family of Herpesviridae is divided in three subfamilies: 
Alpha-, Beta- and Gammaherpesvirinae. Herpesviruses have a wide range of host species and 
cause various clinical signs, ranging from no signs to lethal disease. The crossing of species 
barriers can lead to severe disease in non-adapted species.2 Latency in different cells, such as 
neurons or lymphocytes, and therefore lifelong infection is typical for herpesviruses.2 During 
latency, no infectious virus is excreted, and no viral DNA can be detected. Reactivation of the 
virus leads to virus-shedding by entering the lytic cycle.3 
 
 
1.1.1 Equine Herpesviruses 
Currently nine equine herpesviruses, members of the subfamilies Alpha- and 
Gammaherpesvirinae, are recognized.4 EHV-6 to 8 are also known as asinine herpesvirus 
(AHV, AHV-1 to 3) as they may cause diseases in donkeys. EHV-9 is also called gazelle 
herpesvirus (GHV) and is a pathogen of Thomson’s gazelles (Tab. 1).5-7 
 
 











Equine herpesvirus 1 Asinine herpesvirus 3  
Equid herpesvirus 8  
Gazelle herpesvirus 1 
Equid herpesvirus 9 
Viscerotropic subgroup Equine herpesvirus 4   
Dermatotropic subgroup 
 
Equine herpesvirus 3 
 
Asinine herpesvirus 1  




Equine herpesvirus 2   
 Equine herpesvirus 5 
 
Asinine herpesvirus 2 
Equid herpesvirus 7** 
 
Taxonomy of Equine Herpesviruses (EHV) adapted from Davison et al. (2009)8 and Allen et al (2004).9 The 
nomenclature assigned by the Herpesvirus Study Group of the International Committee on Taxonomy and 
Nomenclature of Viruses (ICTV) is added in italic.10,11 




At least five of the equine herpesviruses shown in Table 1 are described in the literature as 
equine pathogens; three of the subfamiliy Alphaherpesvirinae, namely Equid herpesvirus 1, 3, 
4 (EHV-1,3,4)6 and two of the subfamily Gammaherpesvirinae, namely Equid herpesvirus 2 
and 5 (EHV-2,5).12 Epidemic outbreaks can occur with equine alpha herpesviruses; EHV-1 is 
responsible for abortion, encephalomyelitis,13,14 and respiratory disease outbreaks,6,15 EHV-3 
causes coital exanthema outbreaks,16 and EHV-4 causes respiratory disease outbreaks.17,18 All 
equine Gamma herpesviruses (EHV-2, EHV-5, EHV-7) cause mild respiratory disease in 
young animals and may have a role in the pathogenesis of Equine multinodular pulmonary 
fibrosis (EMPF), a rare interstitial lung disease affecting horses at all ages.19,20 
 
 
1.1.2 Equine Alpha herpesviruses 
The equid alpha herpesviruses 1 and 4 (EHV-1, EHV-4) cause worldwide epidemic outbreaks 
in horses, and have great economic impact on the equine breeding and competition 
industry.8,21-37 The clinical presentations of EHV-1 infections are respiratory disease, abortion, 
neonatal foal death and myeloencephalopathy.14,38-42 Large abortion outbreaks on breeding 
farms, called abortion storms,42-51 as well as outbreaks of Equine Herpes 
Myeloencephalopathy (EHM)39,41,42,52-56 have been reported worldwide. In contrast, EHV-4 
infection mostly remains restricted to the upper respiratory tract and causes a mild upper 
respiratory tract infection that has high morbidity but low mortality. Rarely, abortion due to 
EHV-4 has been reported.25,29,32,33,37 
Typical characteristics of alpha herpesviruses are their efficient and relatively short 
replication cycle as well as latency in sensory neurons, trigeminal ganglion or 
lymphocytes.2,57 The predominantly intra-axonal transmission is reported to be the most 
efficient transmission pathway of all transmission routes. Release of virus from infected cells 
leads to replication and causes cytopathic cell injury, resulting in development of intranuclear 
eosinophilic inclusion bodies.58 In vitro, alpha herpesviruses are able to infect many different 
cell types of various species. In vivo infection with alpha herpesviruses can cause infection in 
various host species however adaption of a virus to a single species is common.58 Situations 
linked to stress, such as transportation, parturition, weaning and others, as well as 





A typical EHV-1 particle consists of approximately 30 discrete kinds of polypeptides.61-63 
Four morphologically distinct components build up the herpesvirus virion; the inner 
nucleoprotein core containing a linear double-stranded genomic desoxyribonucleic acid 
(DNA), the icosahedral capsid, the tegument and the envelope (Fig. 1).64 The size of the 
virion itself is approximately 120nm, combined with the tegument and the envelope the size 
of the virus particle increases up to 300 nm.65 
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Figure 1: The herpesvirus virion 
 
Illustration of the structural components of the herpesvirus virion by Oladunni et al. (2019)66 
 
 
The capsid protein structure and arrangement of every herpesvirus is similar, involving 162 
capsomeres.67 The nucleocapsid contains a ring structure of 12 proteins that allows for the 
viral DNA to enter the capsid.68 The amorphous tegument layer describes the area between 
the nucleocapsid and the envelope and consists of about 12 proteins which are involved in 
early infection stages and viral replication.67 The envelope surrounds the nucleocapsid and the 
tegument and originates from patches of altered host-derived cell membrane.69 Herpesviruses 
obtain their final envelope in the cytoplasm after passing the nuclear membrane. A primary 
envelope is acquired by budding of nucleocapsids at the inner leaflet of the nuclear membrane 
and fusion at the outer leaflet afterwards.70 The eleven embedded glycoproteins (gp) are 
preserved across all alpha herpesviruses and therefore named according to the HSV-1 
nomenclature.67 The envelope gp are relevant components in entering a susceptible host cell, 
determination of host range, virus cell-to-cell spread, pathogenicity and immunologic 
response to infection. EHV-1 encodes an additional glycoprotein 2 (gp2) with homologues 
proteins only in EHV-4 and AHV-3.67 Phylogenetic analysis using the glycoprotein G (gG) 
nucleotid sequences has suggested that AHV-3 is evolutionary much closer related to EHV-1 
than either virus is to EHV-4.71 
 
The full genome sequence of EHV-1 has been published in 1992 and 1998 by Telford et al., 
providing information about the genomic organization of the virus.15,17 The size of the linear 
dsDNA genome of the EHV-1 virus is 150.2 kbp, containing 57% guanine +cytosine.65 The 
genome involves 80 open reading frames (ORFs) encoding 76 different genes.15 Generally, 
the arrangement of the EHV-1 genome is similar to other sequenced herpesviruses except for 
five genes (ORF1, 2, 67, 71 and 75) which are only encoded by EHV-1 with no structural 
homolog detectable in other sequenced herpesviruses.9 The function of some of these genes 
remains unknown but it is supposed that they influence the unique adaption of the EHV-1 
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virus to the horse as their natural host.9 Exemplary, the genomic map of the complete DNA-
sequence of a pathogenic British isolate (strain Ab4) of EHV-1 is pictured by Ata et al. in 
2018 using Snap Gene software program (Fig. 2).72 
 
 
Figure 2: EHV-1 genome map 
Genomic map of a EHV-1 Ab4p strain by Ata et al. (2018)72 
 
 
A single non-synonymous nucleotid (nt) substitution of guanine (G) for adenine (A) at 
position 2254 in the viral DNA polymerase gene, encoded by ORF 30, results in a change of 
asparagine to aspartic acid at amino acid position 752 in the Ab4 strain. This genetic mutation 
in this strain is associated with occurrence of EHM,73 whereas the genetically related non-
neuropathogenic V592 strain is considered less virulent. In a survey, five Welsh Pony mares 
and one foal were challenged intranasally or by aerosol with the V592 isolate and monitored 
clinically and virologically.74 All animals showed exclusively upper respiratory signs. The 
low virulence of this strain compared to highly virulent Ab4 and Army 183 isolates was 
associated with lower degree of endotheliotropism, which might be influenced by host 
immunity.74 The Ab4 strain is also associated with more frequent abortion in mares.75 
 
The genomic architecture of EHV-4 and EHV-1 are similar and a high degree of sequence 
identity (75-90% for most proteins) is reported.71,76 The exception to this are the gG 
homologues, which only show an amino acid identity of 58% but are the only known EHV-1 
and EHV-4 gp to possess strong, type-specific epitopes which can be used for differentiating 





EHV-1 was initially described in 1933 at the Kentucky agriculture experimental station by 
Dimock and Edwards, causing epizootic abortion in mares.78 Almost twenty years later, a 
large abortion outbreak in Spain was recorded, affecting nearly half of a group of 125 mares.79 
The abortion virus was isolated for the first time 16 years later in Western Germany from an 
aborted fetus and two foals that died shortly after birth.80 The association between EHV-1 
respiratory infections and abortion was first recognized in Europe in 1999.81 Since then EHV-
1 outbreaks have been described worldwide. 
 
Due to the close relationship of EHV-1 and EHV-4, they were considered to be the same virus 
or minor variants of a single virus called EHV-1 for a long time. Since 1981, repeated 
investigations have shown distinct differences in the restriction endonuclease fingerprints of 
these two viruses. In the early 1990s, detection of a type-specific antibody response to EHV-4 
gG, enabled differentiation of antibodies present in polyclonal sera. This lack of 
differentiation of the two viruses in early studies has to be considered when interpreting 
results of equine alpha herpesvirus studies of the past.77 
 
Horses are exposed to EHV-1 and EHV-4 very early in life. Epidemiological evidence 
suggest that neonates are exposed to the virus shed by their dams and most of them 
seroconvert by six months of age, even when raised in a vaccinated population.82,83 This is 





Serological surveys conducted within defined populations, confirm a worldwide distribution 
of both viruses.27,30,32,33,83,86-91 The worldwide prevalence ranges from 1 - 90% for EHV-1 and 
26 - 100% for EHV-4. Seroprevalence based on region and age (older than 2 years) for both 




Table 2: Seroprevalence of EHV-1 and -4 based on age and country 
Country/Continent EHV-1  EHV-4  
Australia 26 - 30%85,86,92,93 99 - 100% 86,92-94 
Germany 82%91 95%91 
Israel 1%95 99%95 
New Zealand  21 - 70%30,84,89 90 - 100%30,89 
Spain 51%27 26%27 
Turkey 52%*32 77%*32 
USA 80 - 90%96-98 80 - 90%96 
*examined population includes horses and donkeys 
 
 
Based on these reports EHV-1 appears to have significantly lower seroprevalence than EHV-
4. There are however several factors that complicate interpretation of serological surveys of 
EHV-1 and -4, including a lack of availability of type-specific antibodies in the early 1990s,92 
duration of antibody response, frequency of reactivation of the virus, assay characteristics, 
host factors, season and vaccination status.  
Test characteristics play major role as shown in a study where EHV-4 antibodies were 
overestimated compared to EHV-1 antibodies in a group of experimentally infected ponies 
using the Svanovir ELISA (Svanovir EHV1/EHV4-Ab ELISA, Svanova Biotech AB, 
Sweden).27 Interpretation of data of seroprevalence surveys using conventional antibody tests 
such as virus neutralization and complement fixation are inaccurate.99 Therefore, EHV-4 
specific antibodies rather than EHV-1 immune response could have been measured in some 
older studies.100 Peptide specific Enzyme Linked Immunosorbent Assays (ELISA) are 
currently used to detect specific antibodies against EHV-1 and -4.92 
 
Results from EHV-1 and -4 seroprevalence surveys also have to be interpreted with regards to 
recent vaccination and natural infection.101 After natural EHV-1 infection, the immune 
response conferring protection to reinfection lasts only a few weeks or months. Overall, 
duration of EHV-1 immunity after infection is short, and reinfection may occur after 3 - 6 
months.102,103 No comparable investigations on duration of antibody response for EHV-4 are 
available. EHV-4 may also be more endemic in equine populations compared to EHV-1 due 
to more frequent reactivation of latent EHV-4 infection without coincident disease, as is 
described for herpes simplex virus in humans.104 EHV-4 infection occurs during the whole 
year and causes respiratory disease in a wide range of horses, while EHV-1 infection mainly 
occurs in winter causing abortion among mares in the late stage of gestation.105 Hence, season 




1.1.2.4 Antigen (virus) prevalence 
Prevalence of antigen (virus) detection in healthy horses by PCR out of nasal swabs ranges 
from 0 - 33% for EHV-126 and 0 - 9% for EHV-4.26,106 Virus detection in lymphoid tissue 
from healthy horses ranges from 10 - 54% for EHV-130,34 and 6 - 83% for EHV-4.24,34 In 
animals with respiratory disease, PCR positive results from nasal swabs range from 3 - 7% for 
EHV-128 and 6 - 67% for EHV-4.33,106 EHV-1 and -4 antigen prevalence in nasal swabs from 
healthy horses and horses with respiratory disease in various countries are shown in Table 3 
and 4 respectively. Prevalence of neuropathogenic strains detected in lymphoid tissue, various 
organs of aborted fetuses and horses with EHM are also presented in Table 3 and Table 4. 
Age of the sampled population, vaccination history and differentiation of abortion and EHM 
outbreaks are not shown in these data. 
The neuropathogenic strain of EHV-1 (D752) has a worldwide distribution.
22,24,30,36,44-46,73,107-
109 The estimated prevalence detected in lymphoid tissue from healthy horses ranges from 6 - 
18%.24,30,109 In confirmed EHV-1 outbreaks (EHM and abortion) the median percentage of 




Table 3: Prevalence of EHV-1 and -4 nasal shedding in healthy horses based on PCR 
Country/Continent EHV-1  EHV-1 D752 EHV-4  
Australia   9%110 
Ethiopia 0%26  0%26 
New Zealand 33%30 6%30  
Uruguay  92%24  





Table 4: Prevalence of EHV-1 and -4 nasal shedding in horses with clinical signs compatible 
with EHV-1 infection based on PCR 
Country/Continent EHV-1  EHV-1 D752* EHV-4  
Argentina  7%111  
Australia   6%110 
Brazil  0%55  
Ethiopia 7%26  8%26 
France  24%112  
Germany  11%113  
India  4%44  
Ireland  13%108  
Italy  90%22  
Japan  3%36  
Poland  0 - 3%43,46 67%33 
Turkey  0%48  
UK  27%107  
USA 3%28 11 – 19%114,115  




Latency describes the non-replicative, non-immunogenic stage which allows persistence of 
the virus in the body. Hallmark of latency is the restriction of viral gene expression which 
results in failure to synthesize certain viral proteins and hence absence of infectious virus 
particles.38 EHV infection can become latent in approximately 80% of horses,116 either in 
lymphocytes (both circulating and those in draining lymph nodes) or sensory nerve cell 
bodies.116-118 The trigeminal ganglia are the preferred primary site of EHV-1 latency.119,120 
Latency occurs predominantly in CD5+/CD8+ T-lymphocytes: in 80% of these cells, 
reactivation of EHV-1 could be detected in venous blood by indirect immunofluorescence 
whereas CD5+/CD-8-/CD4- cells are less frequently involved in EHV-1 latency (20%).121 In 
EHV-1 infected horses, the expression of the EHV-1 genome is suppressed and only the 
latency-associated transcripts (LATs) are present in infected cells.67,118,120 
 
Reactivation of virus in a latently infected animal can serve as a source of infection for other 
horses and may or may not be accompanied by clinical signs.59,122 EHM or abortion cases in a 
closed group of horses have occurred without a known external source of EHV-1 infection.123 
Similar epidemiological observations were made on outbreaks at stud farms in Australia and 
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in the UK.124 Both reports conclude that reactivation of a latent infection in one of the mares 
which had been present on the stud for some months was the source of the outbreak.125,126 
Triggers for EHV-1 reactivation are stressful conditions such as transport, sales, competitions, 
pregnancy and parturition127,128 or experimentally administration of high doses of 
glucocorticosteroids.59 
The local reactivation of the virus in the blood vessels of the pregnant uterus can proceed with 
or without concurrent lytic respiratory infection and therefore with or without shedding the 
virus via nasal secretion.127 The initial respiratory infection that lead to latency of the virus 
likely occurred months or years before the abortion or EHM.96 
 
Coinfection with the neuropathogenic EHV-1 D752 and non-neuropathogenic EHV-1 N752 
strain is a common observation.109 Infection with both variants of the virus was shown in a 
case were the mare was shedding a neuropathogenic variant, whilst the aborted fetus was 
positive for a non-neuropathogenic variant.54 On the other hand, latency of the original 
infective strain in submandibular lymph nodes (SLN) in 24 weanlings five years after 
experimental infection was shown.129 
 
Co-infection with other herpesviruses also plays a role in re-activation of latent infections. 
EHV-2 may act as a transactivator for the IE gene promotor on a latent EHV-1 virus.130 
Another study showed that experimental EHV-1 infection was able to reactivate a latent 
EHV-4 infection.131 A recent study from Ireland investigated molecular characterization of 
EHV-1 strains in several outbreaks on selected premises over multiple years.108 Identical 
molecular virus profiles were present in the horses from the same farm within a year, whereas 
virus strains were rarely identical on the same premises in different years. These results 
suggest reintroduction of a new EHV-1 virus strain rather than reactivation or persistent 




EHV-1 is a highly contagious virus and is usually transmitted by direct contact with nasal 
discharge of an infected animal or object. Contaminated feed, water, equipment or aerosols 
are less common routes of transmission.14,18 Large amounts of infectious particles are present 
in fetal and placental tissue from EHV-1 abortions and can be transferred via direct contact 
(e.g. paddock mates) or via fomites (e.g. shoes, clothing of people).9,132 Outbreaks of viral 
respiratory disease are commonly reported in two- and three-year-old horses in training, on 
racing circuit and in race- or show barns, in which horses from different origins are kept 
together in enclosed spaces.96 
 
Investigations of transmission of EHV-1 and -4 in stud farms suggested that both mares and 
foals can act as a pool for virus transmission.86,133 Seroprevalence on a large Thoroughbred 
stud farm revealed more than 99% of mares and foals positive for EHV-4 while only 26% of 
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mares and 11% of foals were tested positive for EHV-1 antibodies.86 Based on the results of 
mare-foal pairs the authors concluded that EHV-1 infection occurred in foals prior to weaning 
at less than five months of age. EHV-1 infection in foals was active and not a residual of 
maternal derivation as the half-life of maternal EHV-1 antibodies in foals’ serum is 31 days 
whereas the average age of the foals was 124 days. EHV-1 antibody positive foals were four 
times more likely to have an EHV-1 antibody positive dam compared to seronegative foals. 
Presumably, mares were a source of EHV-1, from which their foals became infected in these 
cases. Foals with seronegative dams were likely infected due to close contact with other 
infected foals.86 Results of this study suggest that transmission of the virus was a consequence 
of reactivation of a latent EHV-1 infection in a sub-group of the mares, possibly, due to stress 
of parturition, estrous activity or lactation. Close contact of the mares with their foals as well 
as amongst foals is a plausible reason for transmission of the virus.86 Epidemiologically, a 
cyclic but mostly quiet pattern with mares serving as a continuous source of infectious virus 
particles for the foals during the breeding season is suggested. Dams undergo recrudescence 
of latent viral infection in stressful situations like pregnancy/parturition and horizontally 
transmit the virus to the foal.38,67 
 
Whether venereal horizontal transmission by infectious semen or an effect on stallion fertility 
can occur, is unclear. In one study, 13% of 390 semen samples were EHV-1 positive but there 
was no effect on stallion fertility.134 Another study showed shedding of EHV-1 in semen after 
natural infection up to 20 days after onset of fever, but virus isolation from semen was not 
successful.135 
 
There is little information about the duration of EHV-1 nasal shedding in horses with EHM. 
The conventional belief that horses are no longer shedding infectious virus particles when 
showing signs of EHM, should be abandoned. A large outbreak demonstrated the threat of 
nosocomial EHV-1 infection associated with hospitalization of horses with EHM without 
biosecurity precautions. Some horses were still shedding the virus in nasal secretions at the 
time they were hospitalized for EHM and were able to infect other hospitalized horses.136 A 
more recent study showed EHV-1 viral shedding up to nine days after the onset of EHM due 
to natural EHV-1 infection.54 The severity of clinical signs can also not reliably predict 
duration of EHV-1 shedding.54 Hence, it is currently recommended that biosecurity measures 




Negative effects of EHV-1 on the equine industry include interruption of training, especially 
in young athletes due to pyrexia and respiratory signs, and impaired growth of the horse 
population due abortion. Neurologic outbreaks are also a severe threat to the horse industry. 
Deaths of horses, disruption of breeding or training schedules, cancelation of horse events and 
extensive movement restriction with consequently management difficulties at racetracks and 
training facilities may occur.14 
 
 
1.1.2.7 Pathogenesis of EHV-1 and -4 in general 
Initially, infection of the epithelial cells of the nasal mucosa or nasopharynx occurs.137 The 
virus can use different pathways for entering the cell, either directly fuse with the plasma 
membrane or endocytosis followed by fusion with an endosomal membrane.138 The virus uses 
different receptors to enter the cell,139 including equine major histocompatibility complex 1 
(MHC-1) and cellular integrins.138,140 Once the virus is inside the cell, the lytic replicating 
cycle is started, leading to necrosis and inflammatory cellular response. Distinct herpetic 
lesions of mucosal membranes and shedding of infectious particles ensues.101 After infection 
via the respiratory tract, the virus moves into the cells and hence is not accessible for 
neutralizing antibodies or other components of the immune response.141 
 
The predisposition to other secondary bacterial infections due to the local damage of the 
respiratory epithelium has been demonstrated in a survey of respiratory viruses in New 
Zealand horses, in which multiple respiratory pathogens from horses with clinical signs of 
respiratory disease were detected.142 
 
Invasion of the deeper connective tissue occurs by hijacking migrating mononuclear cells.143 
Consequently, EHV-1 can invade the reticuloendothelial system and the lymphatics to infect 
circulating leucocytes and endothelial cells of blood vessels.101,137 Reaching the respiratory 
tract-associated lymphoid organs, a second round of replication in leukocytes starts, leading to 
a state of cell-associated viremia by spreading the virus via lymph and blood-vascular 
circulation.144,145 Viremia enables further transportation to tertiary replication sites, such as 
the vasculature of the pregnant uterus or the Central Nervous System (CNS).143 
 
Pathogenic lesions occur due to vasculitis, thrombosis and ischemic damage.146 A strong, cell-
associated viremia is crucial to the pathogenesis of EHV-1 and is supposed to be the 
determining difference in the pathogenicity of the higher and lower virulent EHV-1 strains as 
well as the closely related EHV-4.143,147,148 The latter replicates mainly in the upper 
respiratory tract and clinical signs other than respiratory disease are uncommon.143,149 An 
experimental trial using nasal mucosal explants as an infection model showed considerable 
spreading of the EHV-1 from the epithelium to the connective through the basement 
membrane where mononuclear leukocytes were infected, while EHV-4 infected leucocytes 




Main clinical signs in horses with EHV-1 and -4 infection are a biphasic fever and mandibular 
lymphadenopathy. The first fever peak is measured 36-48 hours following nasopharyngeal 
instillation of a viral inoculum. Secondary fever occurs between days 5 and 10, when the virus 
is replicating in the peripheral blood mono-nuclear cells. This febrile phase is associated with 
high shedding of either EHV-1 or EHV-4 virus.150 Generally, severity of disease depends on 
age, physical condition of the host, type of infection (primary infection/reinfection or 




1.1.2.8 Respiratory Disease 
The first lytic replication cycle takes place in the respiratory epithelium of the upper airways. 
As early as 12 hours post infection, first progeny virus and viral antigen are detectable in the 
respiratory epithelium of an infected horse and spreading to the respiratory endothelium may 
occur within 24 hours.67,151 Incubation time depends on pathogenicity of the virus strain and 
ranges from 1-3 days152-154 up to 10 days.5 
 
Clinical signs resemble those of other equine viral respiratory pathogens (e.g. influenza virus, 
rhino- or adenovirus and equine arteritis virus) and include primary rhino-pharyngitis and 
tracheobronchitis.96 Although most of infections proceed without clinical signs, some naïvely 
exposed young horses may show coughing and nasal discharge.9,96 Risk factors for EHV-1 
and -4 respiratory outbreaks include overcrowding, heavy parasite burden, poor nutritional 
state, climatic extremes, additional underlying disease and the mingling of animals from 
different social groups.96 After experimental infection using the virulent Ab4 strain of EHV-1, 
fever in a biphasic pattern up to 10 days was observed.152-154 Lymphadenopathy, affecting 
especially submandibular and occasionally retropharyngeal lymph nodes, mucoid and 
mucopurulent nasal discharge, depending on secondary bacterial infection, conjunctivitis and 
serous ocular discharge, accompanied by moderate depression and anorexia, are reported.9 On 
hematologic analysis leucopenia (lymphopenia and neutropenia) may be present and in foals, 
bronchopneumonia is reported in severe cases.155-157 
 
Overall, the course of the disease proceeds acutely with nasal shedding over the first few days 
after infection and prognosis is good with spontaneous recovery after two weeks of onset of 
infection in most of the cases. If secondary bacterial infections occur, recovery is prolonged 
and prognosis undermined.96 Non-specific bronchial hypersensitivity after recovery of an 
EHV-1 infection is an additional reported sequelae which may lead to poor performance 





1.1.2.9 Abortion, Neonatal and Perinatal Disease 
EHV-1 reaches the reproductive tract through cell-associated viremia.159 The virus first causes 
vasculitis in the small vascular network of the glandular endothelium of the microcotyledons 
followed by widespread vasculitis within 9 to 13 days after infection.9,160-162 Microthrombosis 
within blood vessels may support thrombo-ischemic necrosis of the cotyledons and 
intercotyledonary stroma and causing detachment of the fetus from the placenta.162 The fetus 
dies due to anoxia and can be aborted even before any detectable concentrations of virus is 
transferred via the placenta to the fetus.161 Severity of disease depends on different factors 
such as virulence of the EHV-1 strain, magnitude and duration of viremia and the hormonal 
state of the mare.9,67,75 The magnitude of viremia is more important than the duration of 
viremia.75 Hormones like prostaglandin and chorionic gonadotropin (CG) are reported to 
reactivate the virus and initiate abortion.9,67 
 
Due to premature detachment of the fetus from the placenta, stillbirth or birth of weak 
neonatal foals occurs.163 Mares infected with the virus, may abort spontaneously without prior 
signs of respiratory disease.75,161,164,165 The infected foals show multi-organ pathologies and 
shows clinical signs at birth or within 1-2 days of birth.122,166,167 Prognosis is grave and there 
is only supportive therapy with little success for stopping continuous deterioration due to 
severe respiratory distress, diarrhea as well as neurological deficiencies, manifesting in visual 
and vestibular defects.155,159,166 It is proposed, that congenital EHV-1 infection can be 
epizootic and may occur in association with an outbreak of EHV-1 induced abortion.96 Rarely, 




Similar to the spread to the uterus, the cell-associated viremia is also fundamental for invasion 
and efficient spreading to the CNS.102 Due to its intracellular location and exclusively cell to 
cell transmission, the virus remains undetected by the immune system, especially the 
important disease preventing neutralizing antibodies.99,102 Vasculitis in the CNS is a result of 
direct damage of the endothelium during EHV-1 replication or immune complex formation 
(Arthus-type reaction).18 Vasculitis, with or without hemorrhage, edema, microthrombosis 
leading to thrombo-ischemic necrosis are the pathological sequelae.9 
 
Equine Herpes Myeloencephalopathy (EHM) may occur in horses with our without previous 
signs of upper respiratory tract disease or abortion.168 Clinical signs depend on severity and 
location of the pathological damage. Neuropathogenic strains may lead to more severe clinical 
signs but approximately 14 – 24% of EHV-1 strains from horses with EHM do not show the 
genetic mutation.73,148 There is no satisfactory explanation for variable incidence of EHM and 
different clinical manifestations observed during outbreaks.122,169 Clinical signs vary and 
occur in the first week after infection.9,155 Neurological deficits, including temporary ataxia to 
complete paralysis and especially affecting the hindlimbs, urinary and fecal passage problems 
are reported with the peak between day 2 and 3 after onset of clinical signs.9,122,170 Prognosis 
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for non-recumbent horses is good whereas recumbent horses are generally euthanized due to 
further sequelae such as pneumonia, colic or bladder rupture.9,122 
 
An increased likelihood of EHM development in association with more frequent vaccination 
against EHV-1 has been suggested.18,146 This has to interpreted with caution, as it is difficult 
to assess the impact of vaccination alone, isolated from other factors.14 Many factors like age 
of the horse, prior exposure to the virus, individual response to the vaccine and carriage of 




1.1.2.11 Occular Disease 
In some infections with highly virulent EHV-1 strains, foals may show ocular lesions such as 
chorioretinitis and uveitis within 3-5 weeks of upper respiratory tract disease.171 After 
experimental infection with EHV-1, 50 - 90% of horses developed chorioretinal lesions.172 




1.1.2.12 Diagnosis of EHV-1 and -4 
As a single antibody titer alone is not a confirmation of clinical disease, antigen detection is 
necessary for diagnosis of clinical cases. A quick diagnostic technique is preferable for 
clinical cases as a fast diagnosis needs to be achieved to minimize the spread of disease within 
a population of horses. PCR is a useful diagnostic tool for detection of genomic material of 
EHV-1 and can be performed on various sample material such as nasal swabs/nasal discharge, 
aborted fetus, placenta, brain and spinal cord, paraffin-embedded archival tissues and infected 
cell cultures.173-177 By using novel PCR- platforms such as real time PCR (RT-PCR), 
quantification of viral load can be assessed.178 Nucleic acid from a viable and non-viable virus 
can, however, not be distinguished with this method. Agreement between positive PCR results 
and virus isolation is reported between 85 and 90%.9 Particularly in samples with low levels 
of DNA copies, correlation with compatible clinical signs is necessary to confirm a diagnosis. 
RT- PCR is also able to distinguish between the neuropathogenic and non-neuropathogenic 
strain.179,180 Immunofluorescence staining applied on impression smears from nasopharyngeal 
swab is another fast detection technique for detecting viral EHV-1 antigen.9,96 
 
Cell culture followed by virus isolation remains the gold standard but is only recommended 
when investigating EHV-1 outbreaks or for research purposes. For successful virus isolation it 
is necessary to take samples at early stages of the disease. The peak of virus shedding may 
already have passed at the onset of neurological signs and isolation may be impaired by 
interfering local antibodies.124 The cytopathic effect (CPE) appears quickly in cell culture and 
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remains unique for herpes viruses, showing clusters of rapidly enlarging, rounded, and 
detached cells.9 
 
Serologic analyses including ELISA and Virus Neutralization Test (VNT) are recommended 
by OIE for confirmation of EHV-1 clinical cases and infection prevalence surveillance.181 A 
peptide-based ELISA is a simple, very specific, rapid, sensitive and relatively cheap 
serological diagnostic tool that is able to distinguish between EHV-1 and EHV-4.91 
Considering the course of neutralizing antibodies, they rise quickly after natural infection and 
between 5 - 8 days after experimental infection.84 Moreover, they decline rapidly after natural 
infection as well in vaccinated animals. A four-fold increase in paired serology titers taken 
10-14 days apart provides evidence of acute infection. In neurological cases a diagnosis based 
on antibody rise can be difficult as EHM occurs later in the disease and the antibody rise 
might already have occurred.80,146 The antibody concentration can also help in establishing a 




1.1.2.13 Immunity against EHV 
In the early stage of experimental infection with a virulent EHV-1 strain, components of the 
virus are detected within 12 hours post infection (hpi) in regional lymphoid tissue.182,183 This 
suggests close interaction of the virus with the immune system of the host already in the early 
stage of infection. Several in vitro studies showed fast upregulation of pro-inflammatory 
cytokines for example in a endothelial cell model with either neurovirulent or non-
neurovirulent EHV-1 strains 10 hpi184 as well as type -I IFN induction 3 hpi.185-188 
Inflammatory cytokines activate the adaptive immune system for elimination of viral antigen, 
but induction of pathologies may occur due to activation of coagulative responses.66 
 
Three types of immune responses are required for protection against EHV-1, including 
combat of free infectious virus particles by both mucosal and systemic virus neutralizing 
(VN) antibodies as well as cytotoxic T lymphocytes (CTL) to lyse virus infected cells.159 
Response of the humoral immune system by production of specific antibodies against the 
virus remains generally only temporary.189,190 Overall, duration of EHV-1 immunity after 
infection is short and reinfection may occur after 3 - 6 months.102,103 Nevertheless mares with 
EHV-1 abortion normally do not abort in the following year, suggesting that the immune 
response to EHV-1 infection is complex and probably lasts longer.191 There are no reports in 
the literature of a horse being affected by EHM twice within two consecutive years or even 
within a longer time frame. This however has to be interpreted with caution as mortality for 
EHM is high, the disease is rare and horses might be lost to follow up. 
Interestingly, the maternal serum VN antibodies as well as IgG levels decline fast in newborn 
foals and are absent in the third month of life. These antibodies kinetics agree with the 
previous reported half-life of 31 days.192 Therefore determination of the best time frame for 
immunization of foals is important but also difficult, as early infection with EHV-1 and 4 has 
been documented in several cases.82,133 
24 
 
Virus neutralizing antibodies provide protection up to one year but complement-fixing (CF) 
antibodies only last for three months and show cross reactivity with EHV-4. Both antibody 
types are produced within two weeks after infection.190 The humoral immune system 
generally targets the epitopes of the surface of envelope gp of EHV-1 virus and all of these 
antibody isotypes have been detected in EHV-1 infected horses.67,76,193-195 Especially mucosal 
IgA VN antibodies promote important local protection in the upper respiratory tract (URT). 
Reduction in nasopharyngeal virus shedding following intranasal challenge infections of 
ponies 3 and 13 weeks after first infection was observed.196 But once cell-associated viremia 
is established, humoral immunity is inefficient. Therefore, high EHV-1 antibody titers provide 
information about exposure to the virus in the past but do not seem to correlate with 
protection against disease, such as EHM and abortion. There are case reports of clinical EHV-
1 infection with a high titer of neutralizing antibodies.52,66 
 
Elimination of intracellular pathogens requires activation of CTL. A study showed 
upregulation of CTL response after experimental EHV-1 infection with IFN-γ playing a 
central role in activation of antigen-presenting cells and enhancement of the antiviral effects 
of circulating cytotoxic CD8 T - cells.197 Investigation into correlation of level of CTL and 
clinical signs displayed higher concentrations of CTL associated with fewer clinical signs in 
adult ponies after history of EHV-1 infection compared to young ponies with low EHV-1 
specific circulation CTL.198 Quantification of CTL or memory cells may be useful for 




Development of an effective vaccine against herpesvirus infection remains difficult due to 
induction of latency and other strategies of the virus to avoid components of the host innate 
and adaptive immune system.189 Therefore, vaccines have to invoke strong and sustained 
levels of humoral and cell-mediated immunity against the virus as well as block the 
development of cell-associated viremia.66 Modified live vaccine and inactivated whole virus 





Table 5: Current commercially available EHV-1 and EHV-4 vaccines  





IWVV - Prevent abortion caused 
by EHV infection in 
immunocompetent mares 
- Decrease respiratory 
signs and risk of abortion 
- Reduce virus shedding 
after infection with a 
field strain 
- Foals 
• 1st dose: ≤ 6 months (m) 
• 2nd dose: 4 - 6 weeks (w) 
after 1st dose 
• Revaccination every 6 m 
- Pregnant mares: 










IWVV - prevent abortion due to 
EHV-1 infections 
- Prevent respiratory 
infections caused by 
EHV-1p and  
EHV-1b53,202-205 
- Foals 
• 1st dose: 6 m 
• 2nd dose: 3 – 4 w after 1st 
dose 
• 3rd dose: 6 m after the 2nd 
• Revaccination every 12 m 
- Pregnant mares: 








MLV - reduce EHV-1 infection 




- Foals: 2-dose series: 
• 1st dose: ≥ 6m 
• 2nd dose: 3 - 4 m after 1st 
dose 
• Revaccination every 6 m 
- Pregnant mares: 
















Foals: 2-dose series: 
• 1st dose: ≥ 3 m 
• 2nd dose: 3 – 4 w after 1st 
dose 
• Revaccination every 3 m 
- Pregnant mares: 




* TCID50: Tissue culture infectious dose 50% 
AAEP : American Association of Equine Pracitioners 




Virus neutralizing antibody titers of at least 1 in 103 can be achieved by stimulation of the 
humoral immune system by integration of ISCOMs (immune stimulating complexes) in 
inactivated vaccines. A reduction in the amount and duration of virus nasopharyngeal 
shedding was achieved by vaccination using such techniques.190 However, high pre-infection 
VN antibody titers may not be correlated with protection against abortion and duration of cell-
associated viremia following challenge infection with EHV-1.213 
 
A mucosal humoral immune response has been suggested to provide better protection 
compared to VN antibodies. A study analyzed the mucosal humoral immune response of 
weanling foals following experimental infection with virulent EHV-1 or vaccination with 
either an IWVV (Pneumabort K®) or MLV (Rhinomune®) according to different 
protocols.196,214 Finally, all weanlings were challenged intranasally with virulent Army 183 
(A-183). The control group underwent only challenge infection. Virus-specific IgA dominated 
the mucosal antibody response elicited in weanlings inoculated with A183, being detectable at 
up to 3.1 g/mg total IgA 13 weeks after challenge. However, neither inactivated EHV-1 
administered intramuscular nor attenuated EHV-1 administered intranasally induced 
detectable mucosal antibodies.196 
 
Investigations of the same vaccine often showed different results. This is likely due to 
differences in the immunological status of the study population, including animals with 
variable age and unknown history of prior viral exposure.215 Contemporary vaccines 
irrespective of the type, MLV or IWVV, result in a partial protective immune responses, by 
stimulating high titers of circulating VN antibodies. However, most current vaccines are 
unlikely to stimulate cytotoxic effector lymphocytes. The important role of CTL activity in 
terms of protective immune responses has however been recorded in several studies.198,216,217 
 
There are several experimental studies showing that both MLV53,192,209,218 and 
IWVV53,190,192,218-222 vaccines are safe to use and offer at least partial protection. Reduction in 
clinical disease such as abortion in mares and respiratory signs in adult horses and foals are 
reported for both MLV53,223-225 and IWVV.53,190,192,202,219,220,226 Efficient protection against 
disease outbreaks has not yet been demonstrated. Reduced viral shedding has been 
demonstrated in multiple investigations of MLV53,192,209,218 and IWVV53,190,218,219,221 but 
decrease in cell associated viremia is reported in MLV only in one study following a 
challenge trial in previously vaccinated horses with a live attenuated TS German abortion 
isolate (C-147).192,227 Stronger influence on cell associated viremia was more frequent 
demonstrated for inactivated vaccines.190,222,228  
 
A better efficacy of MLV vaccines compared to IWVV has been suggested, but data are 
conflicting. A study investigated reduction of EHV-1 viremia and nasal shedding by 
commercial vaccines: Three groups of 8 yearling ponies each were vaccinated with either an 
MLV (Rhinomune®, Boehringer Ingelheim Vetmedica, Inc.), an IWVV (Pneumabort-K®, 
Pfizer Animal Health) or a placebo in a blinded, randomized challenge trial.53 Both vaccines 
reduced clinical disease and nasal viral shedding but only the IWVV group showed a reduced 
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number of days of viremia.53 However, reduction of clinical signs was greater in the MLV 
group. These findings are supported by a similarly conducted challenge trial, comparing an 
IWVV (Fluvac Innovator 6 combination vaccine, Fort Dodge) and MLV (RhinomuneTM, 
Pfizer) with a placebo.209 Challenge infection was performed by intranasal delivery of 
aerosolized virus isolate obtained from a an EHM case. Neurological signs and fever were 
significantly lower in the MLV compared to the IWVV and control group. Virus shedding 
from the nasopharynx was almost undetectable in the MLV group and significantly lower 
when compared to the IWVV and control groups.209 However, a large vaccination trial 
comparing efficacy of an IWVV (DuvaxynEHV1,4TM, Pfizer) and a MLV (PrevaccinolTM, 
Intervet, MSD) regarding serological response and protection against abortion did not show 
any difference between the two groups.192 Magnitude and duration of humoral response 
assessed by serum neutralization assays and probing for EHV-1-specific IgG isotypes as well 
as incidence of abortion was not significantly different in this investigation. 
 
More recently developed vaccines include an EHV-4 strain in addition to EHV-1. However, 
investigations of efficacy of these combined vaccines focus on EHV-1 with only little 
published data on the EHV-4 content of the vaccine. One study examined the severity of 
clinical disease, serum neutralizing (SN) and CF antibody response and viral shedding in a 
population of mares and foals vaccinated with an EHV-1,4 vaccine (Duvaxyn® EHV-1,4, 
Pfizer), followed by EHV-1 and -4 experimental infection.219 The mares were vaccinated 
three times (5., 7., 9. month of gestation) and infected with an abortogenic Ab4 EHV-1 strain 
whereas the foals received two vaccinations in an interval of 4 weeks and were infected with 
both, a EHV-1 and EHV-4 field strain. Prevention of abortion in mares and respiratory 
disease in foals as well as a clearly reduced duration and amount of nasopharyngeal EHV-1 
and -4 virus shedding were shown.219 Serum neutralizing and complement fixing EHV-1 and -
4 antibody titers were induced two weeks after first vaccination and were boosted after second 
vaccination, however they never reached the concentrations induced after virus challenge.219 
It is suggested, that antibody response is individually variable but generally shorter against 
EHV-1 compared to EHV-4. 
 
In horses, most vaccines, including EHV-1,4, are administered intramuscular. Local intranasal 
vaccine delivery might be a more efficient way to induce local humoral immunity due to 
imitation of natural infection route.215 During the decade of the 1940’s, a hamster-adapted live 
virus vaccine was tested however accompanied by adverse side effects. Intranasal delivery of 
this vaccine to young horses protected them from challenging EHV-1 infection one month 
later. Further infection programs to immunize mares against virus abortion were conducted. 
During the next decade, the incidence of virus abortion was reduced from 15% in 
unvaccinated animals to 1% after vaccination.229-231 However, safety problems concerning 
vaccine-induced abortion continued.232 
 
More recently, a series of efficacy studies using an intranasal MLV containing a German 
abortion isolate (C-147) were conducted.223,227,233 Prevention of abortion in pregnant mares223 
as well as efficacy against respiratory disease of adult horses227 and reduction in clinical 
disease in foals was achieved.233 No significant differences in viral shedding between 
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vaccinated and non-vaccinated mares or foals was shown. Vaccinated foals developed cell 
associated viremia as frequent as unvaccinated animals.223,233 Only the yearlings displayed 
reduced viral shedding and cell associated viremia six weeks after challenge infection 
compared to the non-vaccinated animals.227An intranasal booster has also been suggested as 
an emergency strategy during an EHV-1 or EHV-4 outbreak to limit the spread of infection.215 
Overall results are encouraging but safe use of the vaccine has to be considered and has not 
yet been fully established. 
 
Despite the fact that EHV vaccination cannot completely protect against infection, disease or 
spreading of the virus, overall, vaccination provides a substantial degree of protection in 
horses following exposure to EVH-1 and EHV-4. Widespread vaccination and improved 
management of breeding stock have been reported to reduce abortion storms in the USA by 
75%.5 Similar assumptions are made for Europe, due to reduced amount and duration of viral 
shedding in vaccinated animals.215 In contrast, there are only few investigations regarding 
EHM following vaccination. Supporting published data in terms of efficient protection against 
EHM with any vaccine are missing.52,234-236 
 
A strategy to protect young foals against EHV-1 is to increase amount of maternal antibodies 
in foals by vaccinating the pregnant mare against EHV-1, however the impact of maternal 
antibodies on EHV-1 is not completely understood.192,237 Immunization of the foal is another 
strategy, but generally poor reactivity of the foal’s immune system to primary vaccination is 
reported. Inactivated whole EHV-1,4 or sub-unit vaccinates administered to foals less than 5 
months of age was not successful in mounting an immune response,133,237 however 
vaccination of foals older than 5 months of age with a live-attenuated EHV-1 resulted in some 
degree of protection against signs of disease, reduced virus shedding and presence of cell-
associated viremia after challenge infection with EHV-1.233 The immature antigen presenting 
cell function for foals may contribute to the weak immune responses to vaccination. This has 
been shown in context with the absence of an immune response after vaccination with a DNA 
vaccine against Rhodococcus equi.238 Pre-existing EHV-4 antibodies may also interfere with 
EHV-1 immunization.133 
 
Determination of the best timeframe for immunization of foals include considerations about 
antibody kinetics and subclinical infections in the early age. Half-life of maternally derived 
VN antibodies is less than 4 weeks192 and their absence in the third month of life contrasts 
with early EHV-1,4 infections at the age of 11 days.93 It is currently not known, if these 
subclinical infections lead to cell associated viremia and establishment of latency. If this 
scenario holds true, prevention of latency by vaccination has a very short window of 
opportunity. Overall, the best timeframe for immunization of foals is difficult establish. 
 
The ideal vaccination scheme and type of vaccine are under debate. Recommendations of the 
American Association of Equine Practitioners (AAEP) include vaccination of every horse at 
risk in the following scheme for adult horses (Tab. 6) and foals (Tab. 7).239 The recommended 
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vaccination scheme of the Vetsuisse Faculty of Switzerland is similar to the reference of the 
AAEP and is presented in Table 8.  
 
 
Table 6: Recommended EHV vaccination scheme for adult horses (AAEP, 2020)200 
Broodmares Other adult horses 
(>1 year of age) 
Vaccinated  
Other adult horses 
(>1 year of age) 
Unvaccinated  
Comments 










- 3-dose series:  
• 2nd dose 4-6 
weeks after 1st 
dose 
• 3rd dose 4-6 
weeks after 
2nd dose  
Consider 6-month revaccination 
interval for:  
1) Horses less than 5 years 
of age 
2) Horses on breeding 
farms in contact with 
pregnant mares 
3) Performance or show 
horses at high risk 
 
 
Table 7: Recommended EHV vaccination scheme for foals (AAEP, 2020)240 
Foals (<12 months of age) of mares vaccinated in the prepartum period against EHV abortion as 
well as for foals of unvaccinated mares 
Inactivated or modified live vaccine: 
3-dose series: 
• 1st dose: 4-6 months of age 
• 2nd dose: 4-6 weeks after first dose 
• 2nd dose dose: 10-12 months of age 
• Revaccination at 6-month interval 
 
 
Table 8: Recommended EHV vaccination scheme in Switzerland (Vetsuisse - Konsensus)241 
Broodmares Other adult horses and foals  
Vaccinated (completed BI) 
• 1st dose: 5. month of gestation 
• 2nd dose: 7. month of gestation 
• 3rd dose: 9. Month of gestation  
BI: 2-dose series 
• 1st dose: Generally at the age of 6 months 
In case of high infection pressure or foals of 
unvaccinated mares in large farms earliest at 
the age of 3 months 
• 2nd dose: 3-6 weeks after the first BI 
Not vaccinated before: 3-dose series 
• Initiation of BI as soon as possible 
• 2nd dose of BI: 3-6 weeks after the 1st 
dose 
• 3rd dose: Booster in the 9. month of 
gestation if possible, depending on 
gestation stage 
Booster injection:  
• every 6 months 
 
BI: Basic immunization 
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Virus shedding after EHV vaccination has not yet been investigated but occurs occasionally 




1.1.3 Equine Gamma herpesviruses 
The subfamily Gammaherpesvirinae contains four different generas, named Percavirus, 
Macavirus, Rhadinovirus and Lymphocryptovirus.8 The genera Percavirus include EHV-2, 
EHV-5, EHV-7 (also called AHV-2) and the closely related asinine herpes viruses AHV-4, 
AHV-5 and AHV-6.8,243 Gamma herpesviruses replicate slowly, have a lymphocytic tropism 
and limited host range.58 The gamma herpesviruses prefer latency in T and B cells. However, 
the high seroprevalence to EHV-2 in the equine population relative to the prevalence of the 
detection of its DNA in peripheral blood lymphocytes (PBL) suggests there are other sites of 
latency in addition to leucocytes.244 Cell infection results in cytolytic replication and occurs 
only in a subset of gamma herpesvirus infected cells.245 The subfamily of gamma 
herpesviruses contains more conserved gene regions than the other two subfamilies, but every 
virus of the subfamily gamma herpesvirus has their own set of unique genes, mostly placed at 
the terminal region of the genome. These regions are responsible for the individual viral 
pathogenesis of the virus.69 Development of viral latency by interference with host immune 
and inflammatory response is suggested to be associated with distinct genetic sequences, 
identical to those of eukaryotic cells.246 
 
 
1.1.3.1 Genomic structure 
EHV-2 contains a 184 kbp double-stranded DNA genome with a G+C content of 58% and 79 
ORF encoding 77 proteins.247 The EHV-5 genome is shorter, containing 179 kbp but its G+C 
content is similar.248 There is a 60% shared identity between the EHV-2 and EHv-5 sequences 
at DNA and amino acid levels.12,249 Many genes homologous encoded by both viruses, 
including DNA polymerase, glycoprotein B (gB) or major capsid protein have been 
identified.250 Further similarities between EHV-2 and EHV-5 and γ-EHV contain co-linearity 
in ORF 74, a marked depletion of CpG dinucleotide and a surplus of TpG + CpA 
dinucleotide. 
 
The heterogeneity of gamma herpesviruses is in contrast with the homogeneity of alpha 
herpesviruses. Genomic heterogeneity occurs in both, EHV-2 and EHV-5 and is likely the 
reason why horses can become infected with different strains over their lifetime.251,252 In an 
epidemiologic study of mares and foals held on the same premises, EHV-2 isolates revealed 
significantly more genomic variations than EHV-5 isolates did.252 High frequency of 
recombination among wild strains, even in genomic regions previously characterized stable 
are detected in various EHV-2 isolated from Australia, Hungary, Germany, England and 
Sweden.253 However, by using sequencing of the gB region and restriction fragment length 
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polymorphism (RFLP), genomic variability was also demonstrated in EHV-5 isolates.254 
Despite these variations in gamma herpesviruses common cytopathic properties are shared.12 
 
 
1.1.3.2 Epidemiology and Transmission 
EHV-2 is endemic and the virus has been isolated worldwide.250,255-258 Reported prevalence in 
nasal swabs and Peripheral Blood Mononuclear Cells (PBMC) range from 0% - 77%90,142,257-
259 and 30%-99%90,252,260,261, respectively, depending on geographic location, age and the 
investigated specimens.  
 
EHV-5 was first identified in 1970 and can be detected in healthy horses as well as horses 
with respiratory disease.246 The prevalence of EHV-5 in nasal swabs and PBMC range from 0 
- 100%26,90,142,259,262,263 and 15 – 100%252,260,261, respectively, depending on geographic 
location, age and the investigated specimens. To the authors knowledge, the prevalence of 
EHV-2 and EHV-5 in Switzerland is unknown. 
 
EHV-5 and EHV-2 were both found more often in horses with lower airway inflammation 
compared to healthy horses.264 Horses shedding EHV-2 virus were three times more likely to 
display clinical respiratory disease and is likely to be an important contributor to induce or 
predispose equids to respiratory disease.26 Both viruses can simultaneously infect the same 
animal.251,255,260 
 
The most common route of EHV-2 transmission under field conditions is horizontal transfer 
via nasal and ocular excretion.265,266 However, the nasal mucosa is suggested as the main 
reservoir of virus and source of excretion.256 Investigations on excretion patterns show more 
common re-infection an re-excretion than constant viral shedding.265  
 
Overall, a diagnosis of gamma herpesvirus infection remains difficult to establish, as clinical 
manifestations and epidemiological distribution patterns are various and unspecific.246 Horses 
which test gamma herpesvirus positive during a fever phase with concurrent clinical signs of 
upper respiratory tract disease should be kept isolated from other horses.90 
 
 
1.1.3.3 Pathogenesis and Clinical signs 
The pathogenic potential of EHV-2 in adult horses is suggested to be linked to a modulation 
of the host immune response.267 Common virulence mechanisms of gamma herpesviruses 
include interference with host innate immune response. EHV-2 is able to down-regulate the 
transcription of equine monocyte chemoattractant protein 1,267 produce G protein-coupled 
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receptors247 and stimulation of T-lymphocytes by macrophages, leading to host 
hypersensitivity and chronic secondary respiratory disease.268 The importance of EHV-2 as a 
co-factor of infection or disease has been reinforced by molecular studies, demonstrating 
activation of immediate early genes (IEG) of EHV-1 and EHV-4.116,130 The immediate early 
proteins encoded by these IEG are central to virus replication and its regulation. 
 
Pathogenicity of EHV-2 and EHV-5 is discussed controversial, as both viruses can be 
recovered from both clinically affected and healthy animals.254,269-271 Clinical signs associated 
with both of these viruses are nasal discharge, enlarged lymph nodes and coughing.89,261 
However, correlation between presence of EHV-2 in tracheal washes from 84 horses in 
training and respiratory tract disease failed.272 
 
EHV-2 has been isolated from foals and adult horses with keratoconjunctivitis or respiratory 
tract disease. Severe outbreaks of respiratory diseases in foals with 100% morbidity, 
exhibiting moderate pyrexia, dullness and serous to mucopurulent nasal discharge of several 
days duration are reported.273,274 Other diseases associated with natural EHV-2 infection 
include granulomatous dermatitis275 and abortion.276,277 However, experimental inoculation of 
equine fetuses failed to infect fetus or induce abortion.278 Investigations on duration of EHV-2 
detection following experimental intranasal EHV-2 inoculation in a murine infection model 
showed virus recover up to 30 days from lung, trachea, nasal turbinates and trigeminal 
ganglia. However, long-term latent infection of B lymphocytes was not achieved in this 
model.279,280 
 
EHV-5 is associated with Equine pulmonary fibrosis (EMPF), a rare interstitial lung disease 
affecting horses at all ages.19,20,281-294 Pathogenesis is not completely elucidated, herpesviruses 
are suspected to be involved in pulmonary fibrosis in humans, rodents, and domestic animals 
(dog, cat, horse).295,296 There are similarities between fibrotic disease in these species and 
EMPF in horses regarding the age at clinical onset and progression of the disease as well as 
poor response to therapy.297 Why some horses develop signs of EMPF while others remain 
healthy is unclear. Clinical signs of EMPF depend on the stage of disease and include 
tachypnoea, increased respiratory effort, tachycardia, weight loss/poor overall condition, 
intermittent fever and cough.20,298 Long term prognosis for this horses remains fair to poor.282 
 
AHV-4, AHV-5 and AHV-6 have been detected in donkeys with interstitial pneumonia, with 
lesions similar to EMPF.243,299 Detection of AHV-5 in horses is rarely described. AHV-5 was 
detected in horses with respiratory disorders or “poor performance syndrome”.246 Concurrent 
detection of EHV-5 and AHV-5 in an EMPF case has been described in a case report.283 
AHV-5 has also been detected in lung tissue of a horse with pyogranulomatous pneumonia, a 
pathology differing from described EMPF cases in horses and interstitial pneumonia in 




1.1.3.4 Diagnosis of infection 
EHV-2 and EHV-5 can be diagnosed by indirect methods, such as complement fixing test 
(CFT), neutralizing tests and ELISA as well as cell culture and DNA amplification by PCR 
technique. An ELISA that can discriminate between EHV-2 and EHV-5 has been 
developed256 and a blocking ELISA validated for EHV-2 serodetection is available.301 Cell 
culture are performed by isolation from the PBL of infected horses using co-culture 
techniques252 with added IL-2 to increase sensitivity of detection.261 CPE of EHV-2 are 
usually detected within 12 – 21 days,274 compared to 4 – 12 days with applied co-cultivation 
technique.252 Slow development of CPE with evidence of ballooning over 3 – 4 passages to 
increase amount of available virus is reported in EHV-5 culture.20 Multiplex-PCR has been 
used in epidemiological studies for EHV-2 and EHV-5.302 Most techniques target the gB gene 
region but the the gH region is also commonly used.260 
 
 
1.1.4 Aims of the Study 
The objectives of this study were: 
• To follow the antibody response following EHV-1 and -4 vaccination using different 
vaccination schemes 
• To evaluate post-vaccination virus shedding 





2 Material and Methods  
2.1 PART A - EHV-1 and EHV-4 shedding and antibody response after 
vaccination 
 
The study was performed under the regulations of the Swiss federal authorities for animal 
experimentation (Animal use license no. ZH006/18). 
 
2.1.1 Farms and animals 
24 horses were included in the study, including horses that were vaccinated (n = 18, Group A-
C) and horses that were left unvaccinated (controls, n = 6, Group D). Geographical origin, 
number of horses and vaccination or control status as part of the study as well as vaccination 
history are displayed in Table 9. 
 
 
Table 9: Summary of included farms and animals 
Farm Canton Group n Vaccination 
Protocol (A-D) 
Vaccination history 
1 AG Vaccination 3 A BI > 4 years ago 
Booster q 6months 
2 AG Vaccination 11 B (n = 5) and 
C (n = 6) 
None in the last 2 years 
3 SO Vaccination 3 A BI > 4 years ago 
Booster q 6months 
4 Germany Vaccination 1 C None in the last 2 years 
5 ZH Control 6 D Never vaccinated before 
BI: Basic immunization (two vaccines administered four weeks apart) 
Group A: Booster was continued q 6 months throughout the study 
Group B: Vaccinated two times, six months apart without prior BI 
Group C: BI followed by a booster after six months 
Group D: No vaccination as part of the study 
 
 
Horse owners were contacted through personal contacts of the researchers, recent patients and 
their stable mates at the University of Zurich Teaching Hospital and referring veterinarians. 
Horses were included in the study if owners provided written consent. Inclusion criteria for 
control horses were no EHV-1/4 vaccination history in the last two years and an informed 
decision of the owner to continue management of the horses without EHV vaccination for the 
next 12 months. Inclusion criteria for vaccinated horses were willingness of the owner to 
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continue the current vaccination protocol for at least 12 months (Group A) or willingness to 
agree to a new vaccination protocol in unvaccinated horses (Group B and C). Not all horses 
present on the farms were included in the study due to missing owner consent. Samples were 
collected on farm and the routine management of the horses was not changed. 
 
There was movement of horses off and on all farms during the whole sampling period. The 
herds were therefore not considered closed herds. Reason for animal movement included start 
at competition (Farm 2, 5), additions to the herd (Farm 2, 3, 4, 5), removal of animals from 
the herd (Farm 1, 2, 4, 5) and hospitalization at an equine clinic (Farm 4). On Farm 2 and 5, a 
pregnant mare vaccinated against EHV-1,4 was in contact with the sampled horses. The mare 
of Farm 2 foaled in the last third of the second sampling period whereas in Farm 5 EHV-1 
induced abortion in the last third of the first sampling period occurred. During the first 
sampling period, an outbreak of strangles was diagnosed in Farm 3, including two horses of 
the study population. 
An EHM outbreak had occurred on the farm of Group B and C in 2016, two years before 
sampling of the study was started. Horses that were present at the time of the outbreak (n = 4) 
received EHV-1/4 basic immunization (BI, two vaccines administered four weeks apart) 




All vaccinations were performed with Duvaxyn®EHV-1,4 ad us.vet. (Zoetis Schweiz GmbH, 
Delémont), containing one vaccination dose of 1.5ml solution. The groups were vaccinated as 








Breed (n) Vaccination 
History 










n = 6 
14.5 




BI > 4 years ago 
Booster q 6m 
No Yes Yes 
B 
n = 5 
5 
(2 - 13) 
WB (5) No vaccination 
within last 24m 
No Yes Yes 
C 
n = 7 
11 




within last 24m 
Yes Yes Yes 
D 
n = 6 
12.5 
(7 - 17) 
WB (6) Never vaccinated  No No No 
BI: basic immunization, consisted of 2 vaccines given 4 weeks apart 





An overview of the sampling scheme for blood and nasal swabs are shown in Figure 3 and 4, 
respectively. All horses in Group A and B were studied for a total of 11 months, starting 
immediately before the first vaccination in summer, to five months after the 2nd vaccination in 
winter. Horses in Group C received an additional vaccine due to basic immunization (BI) with 
two doses 4 weeks apart followed by the booster and were therefore followed for a total of 12 
months. 
 
Samples for serologic analysis were obtained at 12 time points from horses in Group A and B. 
The time points were as follows: before the summer vaccination and 1, 2, 3, 4, 5 months after 
the summer vaccination, immediately before the winter vaccination and again 1, 2, 3, 4, 5 
months after the winter vaccination. Horses of Group C were sampled before part one and two 
of the BI and 1, 2, 3, 4, 5 months after the second part of the BI as well as before winter 
vaccination and 1, 2, 3, 4, 5 months after winter vaccination. Therefore, an additional sample 
1 month after the second part of the BI was obtained for this group. Sampling of horses from 
Group D started at a later starting point, followed by the same protocol as Group A and B, but 
no vaccination was performed. The first taken blood sample of every horse in this study is 
defined as the pre-study status. At each time point, 5ml of blood was collected by 
venipuncture of the jugular vein with a Vacutainer and a Vacuette® tube, containing Serum 
Sep Clot Activator (Greiner Bio-One International). Samples were processed within 12 hours. 
Serum was allowed to stand for at least one hour and afterwards centrifugated with a Hermle 
LAB-Z200 A centrifuge for 10 minutes at 3000 rpm. Serum was then poured off in a sample 
tube and stored in a -80°C freezer.   
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To detect EHV-1 and EHV-4 shedding, a nasal swab (eNATTM ® Copan Diagnostics Inc.) was 
collected from every horse before summer and winter vaccination and daily for 5 days after 
summer and winter vaccination. Horses in Group C were sampled before part 1 and 2 of the 
BI and daily for 5 days after BI as well as before winter vaccination and daily for 5 days after 
winter vaccination. Sampling of horses from Group D started at a later starting point, 
followed by the same protocol as Group A and B, but no vaccination was performed. The first 
taken nasal swab of every horse in this study is defined as the pre-study status. Nasal swabs 
were immediately inserted into the virologic medium (Copan eNAT flocked swab 
606CS01R). Samples were stored in a freezer at -80°C. 
 
All serum samples and the nasal swabs prior to vaccination of Group A, B and C were 
obtained by the first author of this study except for one horse on Farm 4 (Group C) from 
which all samples were taken by the owner (veterinarian), and all horses on Farm 2 (Group A) 
from which samples during the second sampling period were taken by the owner (veterinarian 
technician). The nasal swabs after vaccination were obtained by the owners, nasal swabs were 
provided to the owners for collection. 
All serum and nasal swabs samples of Group D were taken by the barn veterinarian as per 
wishes of the owners. 
 
 
Figure 3: Schematic representation of sampling timepoint for serological analysis in 18 
horses vaccinated against EHV-1 and EHV-4 
m: months; Vacc: Vaccination; preVacc: pre vaccination; mpostVacc: months post vaccination 
Group A and B received 2 vaccines; a summer and a winter vaccine six months apart (VaccS and VaccW), 
Group C was administered 3 vaccines, including a two-part BI 4 weeks apart (VaccBI1, VaccBI2) and a winter 
vaccine (VaccW). In Group C an additional blood sample (12m) were collected due to the additional vaccine. 
The booster immunization of Group C lead to a shift of the sampling timepoints compared to the scheme of 





Figure 4: Schematic representation of sampling timepoints for evaluation of nasal shedding 
of EHV-1 and EHV-4 in 18 vaccinated horses 
 
d: days; Vacc: Vaccination; preVacc: pre vaccination; dpostVacc: days post vaccination 
Group A and B received 2 vaccines; a summer and a winter vaccine six months apart (VaccS and VaccW), 
Group C was administered 3 vaccines, including a two-part BI 4 weeks apart (VaccBI1, VaccBI2) and a winter 
vaccine (VaccW). In Group C six extra nasal swabs (preVaccBI2, 1-5dpostVaccBI2) were collected due to the 




2.1.3.1 Sampling procedure 
Samples were taken without wearing gloves and always in the same order, starting with the 
nasal swab, followed by obtaining the blood samples. At the time points when the vaccine 
was administered the chronology of sampling was as follows: 
1. Completion of the passport of every horse including transfer of the sticker from the 
vaccination bottle into the passport. 
2. Preparation of the vaccine by drawing the liquid into a syringe 
3. Sample collection (nasal swab then blood sample) 
4. Administration of the vaccine. 
 
After results became available an additional experiment was performed to evaluate potential 
contamination of the nasal swab with EHV-1 and EHV-4 DNA during the sampling 
procedure. An EHV-1,4 vaccine vial (Duvaxyn®EHV-1,4, Zoetis) and a tetanus vaccine vial 
(Equilis®Te, MSD) were investigated for presence of EHV-1/4 DNA on the surface of the 
vaccine bottle. Before starting the trial, gloves of the researcher were sampled to rule out 
previous contamination. The outside of the Duvaxyn vaccine vial and Tetanus vaccine vial as 
well as the gloves of the researcher after handling the bottles to remove the sticker and draw 
the liquid into the syringe were swabbed with eNAT swabs. The content of both vaccine 
bottles was tested with two different swabs, eNAT (eNATTM ® Copan Diagnostics Inc) and 
UTM (UTM® Copan Diagnostics Inc), these samples served as positive and negative 
controls. The eNAT swabs contain a medium to preserve nucleic acid, therefore suitable for 
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genome detection. The UTM swab conserves and maintain virus particles infectious, therefore 
appropriate for virus isolation on cell culture but also useable for genome detection. Both 
swabs were used to exclude contamination of the swab or medium leading to false positive 
results as well as to assess, if a similar PCR reaction result is achieved with both swabs 
contaminated by the vaccine virus. The gloves were changed after each step to control every 
individual operation. The samples were analyzed immediately following the same procedure 
as the nasal swabs. 
 
 
2.1.4 DNA detection of EHV-1 and EHV-4 (real-time PCR) 
DNA was extracted with a commercial Qiamp DNA mini kit (Qiagen, city), according to the 
manufacturer’s instructions. Real-time PCR was performed to test for presence and quantity 
of EHV-1 and/or EHV-4 and a housekeeping gene in the sample. Two PCR reaction mixes, 
one multiplex PCR for EHV (Tab. 11) and one for equine-12S (eq-12S; Tab. 12) as the 
housekeeping gene were prepared. The master mixes consisted of the TaqMan® Universal 
PCR Master Mix (Applied Biosystems; Tab. 11 and 12). The EHV-1 and EHV-4 specific 
primers and probes targeting glycpoprotein B used in this study have been previously 
described.303 The eq-12S primers and probes were designed in-house for a prior study using 
primerExpress software (ThermoFisher) according to Table 13. Extracted DNA of an EHV-1 
and an EHV-4 infected horse in 1:10 dilution were added as positive controls. The Eq-12S 
positive control was used in a dilution of 1:100 and Diethylpyrocarbonate (DEPC) treated 
water was used as a negative control. 
 
PCR was performed in 45 cyles with the QuantStudio 7 real-time PCR machine. Cycling 






Table 11: PCR Master Mix EHV-1/4 
EHV-Mix (number of samples + 5 
controls + 1) 
1x sample 
(μl) 
2x Universal Mix 10 
EHV-1 F primer (20uM) 0.4 
EHV-1 R primer (20uM) 0.4 
EHV-1 probe-FAM (10uM) 0.2 
EHV-4 F primer (20uM) 0,8 
EHV-4 R primer (20uM) 0,8 
EHV-4 probe-VIC (10uM) 0.4 
Nuclease-free water 2 
Final volume mix 15 
DNA 5 
F: Forward, R: Reverse 
 
 
Table 12: PCR Master Mix eq12S 
eq12S-Mix (number of 
samples+3controls+1) 
1x sample (μl) 
2x Universal Mix 10 
e12S F primer (10um) 1 
e12S R primer (10um) 1 
e12S probe (5um) 1 
Nuclease-free water 5 
Final volume mix 18 
DNA 2 





Table 13: Primer sequences for EHV-1/4 and eq12S PCR 
Name Sequence 5’->3’ Start End Reference 
EHV-1 F primer CATGTCAACGCACTCCCA 1247 1264 D00401.1 
EHV-1 R primer GGGTCGGGCGTTTCTGT 1293 1309 D00401.1 
EHV-1 probe FAM-CCCTACGCTGCTCC-MGB 1277 1290 D00401.1 
EHV-4 F primer GGGCTATTGGATTACAGCGAGAT 2571 2593 M26171.1 
EHV-4 R primer TAGAATCGGAGGGCGTGAAG 2610 2629 M26171.1 
EHV-4 probe VIC-CAGCGCCGTAACCAG-MGB 2595 2609 M26171.1 
e 12S F primer GGAGCCTGTTCCATAATCGATAA 555 577 X79547.1 
e12S R primer GTTTGCTGAAGATGGCGGTATAT 638 616 X79547.1 
e12S probe FAM-TAAACCCCACCATCCCTTGCTAATTC 
AGC-TAMRA 
585 613 X79547.1 
Primer sequences for EHV-1/4 and eq12S PCR used to detect viral shedding before and after vaccination of 18 
vaccinated horses and 6 unvaccinated controls. 
F: Forward, R: Reverse 
 
 
Table 14: Cycles of PCR. 
 Temp. °C Duration Unit Cycles 
Hold Stage 50 2 min  
95 10 min  
PCR Stage 95 15 sec 
45x 
60 60 sec 
 
 
2.1.5 EHV-1 and EHV-4 antibody detection (ELISA) 
The sera were tested using a commercially available ELISA Kit (Svanovir EHV1/EHV4-Ab 
ELISA kit, company, city) for presence and concentration of antibodies against EHV-4 and/or 
EHV-1 according to the manufacturer’s instructions. The optical density (OD)-values were 
measured in a photometer at 450 nm. OD-values of the EHV-1 and EHV-4 coated wells from 
each sample were corrected with the value of the respective negatively coated well according 
to the manufacturer’s instructions, resulting in “corrected OD-values”: 




For validity of the test, the controls were assumed as: “ODcorr Positve Control > 0,6 and ODcorr 
Negative Control < 0,1”. A sample was considered positive if ODcorr is > 0,2 and negative if 
ODcorr is < 0,1. An ODcorr between 0,1 - 0,2 was considered doubtful;
92,304 the manufacturer 
recommends retesting of the animal at a later time point in these cases. As retesting was not 
possible in this study, we designated these questionable results as non-interpretable (nip) and 
elected to present them separately. A peak in serological response was defined by the author 
of the study as a raise in titers of ≥ 0.5 OD-Values.  
 
 
2.1.6 Statistical analysis 





2.2 Part B – Screening for equine gamma herpesviruses in healthy horses 
2.2.1 Farms and animals 
Previously extracted DNA from 68 nasal swabs collected as part of a different project in 2017 
were used. The nasal swabs originated from healthy horses from six Swiss cantons 
(Baselland, Thurgau, Uri, Zurich, Aargau, Waadt) from twelve farms (BL, TG, UR 1, UR 2, 
ZH 1, ZH 2, ZH3, ZH4, AG1, AG2, VD1, VD2) and from horses from two farms (DE1, DE2) 
with an EHV-1 outbreak in Germany (Fig. 5). 
 
 
Figure 5: Geographical distribution of the stables of horses screened for shedding of equine 
gamma herpesviruses 
 
AG: Aargau; BL: Baselland; DE: Germany; TG: Thurgau; UR: Uri; VD: Waadt; ZH: Zurich 
ZH 1 (3): Zurich, barn number, number of sampled horses per barn 
 
 
DNA extraction from the nasal swabs was performed as part of a different project using a 
commercial DNA extraction kit (Qiamp DNA mini kit, Qiagen, city) according to the 
manufacturer’s instructions. DNA was stored at –80°C and had only undergone one thawing 




2.2.2 Panherpes nested PCR 
A Panherpes nested PCR was performed as previously described.305,306 This PCR targets a 
highly conserved region of the herpesviral DNA polymerase gene. As degenerate consensus 
primers are used, the PCR is capable of detecting known and novel herpesviruses without 
prior information on DNA sequence.307 This nested format with two forward (DFA and ILK) 
and one reverse (KG1) degenerate primer in the first PCR and one forward (TGV) and one 
reverse degenerated primer (IYG) in the second PCR is shown in Figure 6.305 Primer 
sequences are shown in Table 11.305 The expected size of the product after Panherpes nested 
PCR is 215-235 bp.306 
 
 
Figure 6: Relative position of the PCR priming sites in the nested format (VanDevanter, 
1996)305 
Relative positions of PCR priming sites for DFA, ILK, KG, TGV, and IYG primers (arrows) within an amino 
acid-coding map of the human herpesvirus 1 DNA polymerase gene 305. Previously described 308 coding motifs 
conserved across broad classes of DNA-dependent DNA polymerases (Exo I, II, II9, and III and motifs A, B, and 
C) are noted with open boxes. The region obtained by nested consensus primer PCR with the indicated primers is 




Table 15: Primer sequences for Panherpes nested PCR (VanDevanter, 1996)305 
PCR Primer Primer Name Sequence 
1. 
Forward DFA 5’- GAY TTY GCN AGY YTN TAY CC-3’ 
Forward ILK 5’- TCC TGG ACA AGC ARN YSG CNM TNA A-3’ 
Reverse KG1 5’- GTC TTG CTC ACC AGN TCN ACN CCY TT-3’ 
2. 
Forward TGV 5’- TGT AAC TCG GTG TAY GGN TTY CAN GGN GT-3’ 
Reverse IYG 5’- CAC AGA GTC CGT RTC NCC RTA DAT-3’ 
 
 
A minor modification to the reaction mixes described by Ehlers et al. (1999)306 was made. In 
the first PCR round, 5 µl of extracted sample DNA were used and for the second PCR round 
1µl of the product from the first round was applied. The final volume of both mixtures added 
up to 25µl and contained 2.5µl PCR Buffer (10x, Qiagen, Hombrechtikon, Switzerland), 
200µM of each deoxynucleotide triphosphate, 1µM of each primer and 2 units HotStarTaq 
DNA Polymerase (5U/µl, Qiagen, Hombrechtikon, Switzerland). DEPC treated water was 
added as needed to reach the final reaction volume of 25 µl. DEPC treated water was used as 
negative control and DNA extracted from a cow with confirmed bovine malignant catarrhal 
fever (BMCF) was used as a positive control. 
The Peltier Thermal Cycler-200 (MJ Research) was used for thermal cycling according the 
protocol of Ehlers et al. (1999)306 with a minor modification. The initial denaturation time was 
12 minutes at 95°C instead of 3 minutes at 95°C. Before loading the products from the second 
PCR on a 2% agarose-gel, containing Gel Red (1000x, Biotium, Hayward CA, USA), 5µl of 
Orange Loading Dye (6x, Thermo Fisher Scientific, Waltham MA, USA) was added. A 50bp 
DNA Ladder (New England Biolabs) was used. Electrophoresis took approximately two 
hours at 100V. Visualization of bands with the expected size (215 - 235bp) was performed 
under UV light. 
 
Positive samples, except the positive control, were cut from the gel with a sterile scalpel 
blade. DNA was extracted from the Gel with a QIAquick® Gel Extraction Kit according to 
the manufacturer's instructions (Qiagen, Hombrechtikon, Switzerland). Elution of the DNA 
was performed with 30µl of elution buffer, followed by the third PCR applying non-




Table 16: Primer sequences for the third (sequencing) PCR (VanDevanter, 1996)305 
Primer Primer Name Sequence 
Forward TGVseq 5’- CAT CTG ATG TAA CTC GGT GTA-3’ 
Reverse IYGseq 5’- GAC AAA CAC AGA CTC CGT-3’ 
 
 
The reaction mixture for the third PCR was similar to the one delineated for the second PCR 
described above. The only exception was the use of 200 µM of each sequencing primer and 1 
unit of HotStarTaq DNA Polymerase (5 U/µl). A commercial QIAquick® PCR Purification 
Kit (Qiagen, Hombrechtikon, Switzerland) was used to purify DNA and subsequent eluting 
with 30 µl of elution buffer was performed. The total amount of amplified DNA was 
measured in Nanodrop (ND-1000 Spectrophotometer, Scientific AG, Kloten, Switzerland). Of 
each positive sample 45 ng of DNA was mixed with 3 µM of sequencing primer forward (10 
µM, 5´CAT CTG ATG TAA CTC GGT GTA 3´) and filled up with DEPC to a final volume 
of 15 µl. Sequencing was performed by Microsynth (Balgach, Switzerland) and analysis was 
performed with NCBI BLAST® (https://blast.ncbi.nlm.nih.gov/Blast.cgi). Samples were 
determined to be positive if a band was visible in the expected size in the agarose-gel with or 
without a high identity to herpesviral sequences deposited in GenBank. 
 
 
2.2.3 Statistical analysis 









Of the initially included 24 horses (18 vaccinated and 6 controls), 20 completed the study (15 
vaccinated and 5 controls). Two horses were sold (Group A and B), one horse moved abroad 
(Group D), and one horse was euthanized due to chronic lameness during the study period 
(Group C). In one horse of Group C (H21), the period between the basic immunization was 2 
months instead of the planned one month, as the horse was hospitalized when the second BI 
was planned. This horse remained in the study. 
 
Four horses (2 of Group A, 1 of Group B, 1 of Group C) had all serum and nasal swabs 
available. Six serum samples from six horses (Group B, and D) were not collected due to one 
horse being absent at a competition at the sampling time (n = 1/6), and human error (n = 5/6). 
The latter contained all samples of the control Group at beginning of the winter sampling 
period. Forty-eight nasal swabs of 16 horses (Group A, B, C and D) could not be analysed due 
to missing samples from horses who were absent from the barn at the sampling time point (n 
= 9/48), human error resulting in an incorrect sampling timepoint (n = 30/48) or sampling 
material (n=4/48) and lack of cooperation (n = 5/48). Incorrect sampling material was 
obtained when nasal swabs were inserted into the wrong transport medium due to human 
error. Sampling at an incorrect timepoint occurred due to human error resulting in monthly 
sampling instead of daily sampling after vaccination of the first three horses. A more detailed 
presentation of all missing serum samples and nasal swabs that could not be analysed is 
presented in Table 17. An overview of all available samples from every horse is presented in 




Table 17: Overview of missing samples from horses (n=20) included in a study on nasal 
shedding and antibody kinetics after vaccination against EHV-1 and EHV-4 
Horse 
(n = 20) 
Group Missing nasal 
swabs (n = 48) 
Missing serum 
samples (n = 6) 
reason 
H1 D 1 1 competition (NS) 
incorrect sampling timepoint (S) 
H2 D 1 1 competition (NS) 
human error (S) 
H3 D 1 1 competition (NS) 
human error (S) 
H4 D 1 1 competition (NS) 
human error (S) 
H6 D 1 1 competition (NS) 
incorrect sampling timepoint (S) 
H7 C 1 0 incorrect sample material 
H8 C 5 0 lack of cooperation 
H9 C 1 0 incorrect sample material 
H10 C 0 0 all samples available 
H11 C 1 0 incorrect sample material 
H12 B 6 0 incorrect sampling timepoint 
H13 B 6 0 incorrect sampling timepoint 
H14 B 6 0 incorrect sampling timepoint 
H16 B 0 0 all samples available 
H17 B 1 0 competition  
H18 B 3 1 competition (NS and S) 
H19 B 1 0 incorrect sample material 
H21 C 12 0 incorrect sampling timepoint 
H22 A 0 0 all samples available 
H23 A 0 0 all samples available 
NS: nasal swabs; S: Serum samples; H1-21: Horse designation 
Group A: BI >4 years ago, q6months booster which continued throughout the study 
Group B: No vaccination history, vaccinated two times, six months apart without prior BI  
Group C: No vaccination history, BI in summer followed by a booster after six months 
Group D: No vaccination history and no vaccination as part of the study, natural exposure due to an 
outbreak occurred in the middle of timepoint 3mpostVaccS and 4mpostVaccS  
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3.1.2 Adverse reaction to the vaccine 
One horse in Group C (H7) showed an adverse reaction after administration of the first 
vaccine. Swelling at the injection side with a diameter up to 10cm, elevation of the rectal 
temperature up to 40°C for four days, reduced general condition, inappetence and stiff gait 
were recorded. This horse was present but not clinically affected during the EHM outbreak in 
2016 and received basic immunization following the outbreak without recorded adverse 
reaction at the time. 
 
3.1.3 EHV outbreak in control Group D 
Abortion due to EHV-1 infection occurred in the population of the control group (Group D) 
14 weeks after starting the study. The affected mare was not part of the study but in close 
contact to the sampled horses due to group housing of the animals. After confirmation of 
EHV-1 abortion, the mare was separated from the rest of the group. There were no other 
pregnant mares on the farm at the time and none of the other horses developed clinical signs. 
Sampling was continued following the reported outbreak according to initial study design. 
Instead of considering this group an unvaccinated control Group, the Group was now 
considered as naturally exposed. 
 
3.1.4 Serological EHV-1 response after vaccination 
Of a total of 240 samples (Group A-D), 80 Samples were positive, and 135 samples were 
negative and 25 were considered non interpretable (nip). Thirteen nip results were collected 
from vaccinated horses of Group B and C, another 12 from control Group D. 
 
3.1.4.1 Pre-study antibody status 
All serological results prior to the first vaccination of the study protocol (Group A – C) and 
start of sampling in the control group are defined as pre-study status. Overall, 5/18 (28%) of 
horses had a positive pre-study status, 2/5 were in Group A with a regular vaccination history, 
and one each in Group B - D without prior vaccination in the last 2 years. A positive pre-study 
status was more common in horses from in Group A which received the BI more than 4 years 
ago and booster vaccinations every six months since (including during the study period) 
compared to horses that were not vaccinated (Group B - D). Pre-study status of control Group 
was comparable to Group B and C. 
 
3.1.4.2 Serological results of sample groups 
After vaccination 8/15 (53%) of horses were seropositive on at least one timepoint, and 3/15 
(20%) were positive at all time points. In Group D which was naturally exposed during the 
outbreak 3/5 (60%) of horses were positive on at least one time point after the exposure and 
1/5 (20%) were positive at all timepoints after the exposure. EHV-1 seroprevalence based on 
vaccination group and timepoint is shown in Table 19. 
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After both vaccinations Group A and B had a higher seroprevalence than Group C, despite the 
fact that horses in group C were vaccinated with a BI followed by boosters. However, 10/25 
nip results were collected from horses of Group C., including one horse of this Group 
showing 6 nip results. In horses of Group A, no nip results were measured. 
 
A higher seroprevalence was seen in Group D 8 weeks after the outbreak occurred (sampling 
time point 5mpostVaccS/5mpostVaccBI2) compared to Group A-C. Seroprevalence however 
dropped 8 weeks later (sampling time point 1mpostVaccW) and was lower to the vaccinated 
Groups A and B, but higher than Group C.   
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Table 19: EHV-1 seroprevalence in 20 horses vaccinated against EHV-1/4 with three 
different protocols or exposed to EHV-1 at various timepoints 
EHV-1 
Timepoint of sampling 
A (n = 5) B (n = 4) C (n = 6) D (n = 5) Total A-C 
(n = 15) 
preVaccS/preVaccBI1 40% (2/5) 33% (1/3) 17% (1/6) 25% (1/4) 29% (4/14) 
preVaccBI2   25% (1/4)   
1mpostVaccS/1mpostVaccBI2 60% (3/5) 50% (2/4) 50% (2/4) 50% (2/4) 54% (7/13) 
2mpostVaccS/2mpostVaccBI2 40% (2/5) 67% (2/3) 20% (1/5) 0% (0/4) 38% (5/13) 
3mpostVaccS/3mpostVaccBI2 40% (2/5) 67% (2/3)* 20% (1/5) 50% (2/4) 38% (5/13) 
4mpostVaccS/4mpostVaccBI2 40% (2/5) 67% (2/3) 17% (1/6) 67% (2/3)** 36% (5/14) 
5mpostVaccS/5mpostVaccBI2 40% (2/5) 50% (2/4) 33% (2/6) 75% (3/4) 40% (6/15) 
preVaccW 40% (2/5) 25% (1/4) 0% (0/5) missing 
samples 
21% (3/14) 
1mpostVaccW 40% (2/5) 50% (2/4) 20% (1/5) 25% (1/4) 36% (5/14) 
2mpostVaccW 40% (2/5) 50% (2/4) 20% (1/5) 50% (2/4) 36% (5/14) 
3mpostVaccW 40% (2/5) 50% (2/4) 25% (1/4) 40% (2/5) 38% (5/13) 
4mpostVaccW 40% (2/5) 50% (2/4) 17% (1/6) 50% (2/4) 33% (5/15) 
5mpostVaccW 40% (2/5) 50% (2/4) 17% (1/6) 50% (2/4) 33% (5/15) 
preVaccS: pre summer vaccination; mpostVaccS: months post summer vaccination; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); 
preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only); 
mpostVaccBI2: months after the second dose of the basic immunization (Group C only); 
BI: Basic immunization consisting of two doses given 4 weeks apart 
Group A: BI >4 years ago, q6months booster which continued throughout the study 
Group B: No vaccination history, vaccinated two times, six months apart without prior BI  
Group C: No vaccination history, BI in summer followed by a booster after six months 
Group D: No vaccination history and no vaccination as part of the study, natural exposure due to an 
outbreak occurred in the middle of timepoint 3mpostVaccS and 4mpostVaccS 
*The total number of animals varies due to one missing serum sample 
** First sample 2 weeks after an outbreak of EHV-1 occurred in the barn 




3.1.4.3 Serological results of single animals 
In the vaccinated Groups A-C 8/15 (53%) horses showed a serological response to 
vaccination in summer. A sustained rise after vaccination over the whole sampling period was 
seen in 5/8 (63%) of the seropositive horses, the other three animals (38%) were positive only 
at one single sample timepoint (Fig. 7). After winter vaccination 5/15 (33%) showed a 
response, and all of them showed a sustained response over the whole period. 
 
 
Figure 7: Longitudinal EHV-1 antibody concentrations in horses vaccinated against EHV-1/4 
with different protocols (n = 15) 
 
H: Horse number; BI: Basic immunization consisting of two vaccine doses administered 4 weeks apart 
(VaccBI1, VaccBI2); VaccS: summer vaccination; VaccW: winter vaccination, preVaccS: pre summer 
vaccination; mpostVaccS: months post summer vaccination; preVaccW: pre winter vaccination; mpostVaccW: 
months post winter vaccination, preVaccBI1: pre vaccination with the first dose of the basic immunization 
(Group C only); preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only), 
mpostVaccBI2: months after the second dose of the basic immunization (Group C only); OD: Optical density 
Shades of blue: Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued 
throughout the study; Shades of yellow: Group B (H16, 17, 18, 19), no vaccination history, vaccinated two 
times, six months apart without prior BI; Shades of purple: Group C (H7, 8, 9, 10, 11, 21) no vaccination history, 
BI in summer followed by a booster after six months 




In the following figures (Fig. 8 - 11) individual serological response of every horse is shown 
based on vaccination group. 
 
 
3.1.4.4 Group A – Basic immunization > 4 years ago with boosters every 6 months 
In group A 2/5 (40%) of horses showed a sustained high EHV-1 antibody concentration (OD-
Value > 0.2) over the whole sampling period. One horse was seropositive at one timepoint 
(one month after summer vaccination). The remaining two horses were negative at every 
timepoint after winter and summer vaccination (Fig. 8). 
 
 
Figure 8: Longitudinal EHV-1 antibody concentrations of horses in Group A (regular pre-
study vaccinations) which received a summer and winter vaccination during the study (n = 5) 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; preVaccS: pre summer vaccination; 
mpostVaccS: months post summer vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post 
winter vaccination; OD: Optical density 




3.1.4.5 Group B – no vaccination history, vaccinated twice 6 months apart 
In Group B 2/4 (50%) horses showed a serological response to both vaccinations and 
remained positive over the whole sampling period. One of them had a positive EHV-1 
antibodies pre-study status, the other did not. The remaining two horses had a negative pre-
study status and did not show a serological response to either vaccination (Fig. 9). 
 
 
Figure 9: Longitudinal EHV-1 antibody concentrations of horses in Group B (no pre-study 
vaccinations) which received a summer and winter vaccination during the study (n = 4) 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; preVaccS: pre summer vaccination; 
mpostVaccS: months post summer vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post 
winter vaccination; OD: Optical density 




3.1.4.6 Group C – no vaccination history, vaccinated with BI followed by a booster 6 months 
later 
In Group C 3/6 (50%) horses showed a serological response to summer vaccination. Only one 
of these horses showed a consistent high EHV-1 antibody titer (OD-Value > 0.2), this horse 
had a positive EHV-1 pre-study status and was the only animal which showed side effects to 
the vaccination. That same horse also showed a serological response after the second 
vaccination, while none of the other horses showed any response (Fig. 10). 
 
 
Figure 10: Longitudinal EHV-1 antibody concentrations of horses in Group C (no pre-study 
vacinations) which received a two-step basic immunization in summer followed by a booster 
in winter (n = 6) 
H: Horse number; VaccBI1: first dose of basic immunization; VaccBI2: second dose of the basic immunization; 
VaccW: winter vaccination; preVaccBI1: pre vaccination with the first dose of the basic immunization; 
preVacBI2: pre vaccination with the second dose of the basic immunization; mpostVaccBI2: months after the 
second dose of the basic immunization; preVaccW: pre winter vaccination; mpostVaccW: months post winter 
vaccination; OD: Optical density 





3.1.4.7 Group D – No vaccination history, natural exposure 
EHV-1 abortion occurred in the barn of Group D during the last third of the Summer 
sampling period (between sampling timepoint 3mS and 4mS). Two of five (40%) horses had 
EHV-1 antibodies at the time point before EHV-1 abortion occurred, 1/5 (20%) had a non-
interpretable result. Only 1/5 horses in the barn, a horse that already had antibodies before the 
outbreak, showed a strong serological response after the EHV-1 abortion which lasted for at 
least 7 months. All other horses remained negative or had antibody concentrations similar to 
before the abortion. Interestingly one horse showed a sudden spike in antibodies with a slow 
decline afterwards in the second sampling period, unrelated to known natural exposure or 
vaccination (Fig. 11). 
 
 
Figure 11: Longitudinal EHV-1 antibody concentrations of horses in control Group D (no 
pre-study vaccinations; n = 5) which received no vaccinations during the study but may have 
been exposed to virus by an EHV-1 abortion in the same stable.
 
H: Horse number; preVaccS: pre summer vaccination; mpostVaccS: months post summer vaccination; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; No vaccination history and no 
vaccination as part of the study; natural exposure due to an outbreak occurred in the middle of timepoint 
3mpostVaccS and 4mpostVaccS;  
OD: Optical density 




3.1.5 Serological EHV-4 response after vaccination 
All horses had a positive EHV-4 pre-study status and all were seropositive following 
vaccination at all time points. There were no non interpretable results. 
 
3.1.5.1 Serological results of single animals 
In every vaccination group, a distinct EHV-4 antibody rise was seen two months after summer 
vaccination (2mpostVaccS; A, B) or a month after the second BI (1mpostVaccBI2; Group C). 
After summer vaccination 10/15 horses (67%) showed a serological response, after winter 
vaccination 7/15 (47%) horses showed a response (Fig. 12).  
 
 
Figure 12: Longitudinal EHV-4 antibody concentrations in horses vaccinated against EHV-
1/4 with different protocols (n = 15) 
H: Horse number; BI: Basic immunization consisting of two vaccine doses administered 4 weeks apart 
(VaccBI1, VaccBI2); VaccS: summer vaccination; VaccW: winter vaccination, preVaccS: pre summer 
vaccination; mpostVaccS: months post summer vaccination; preVaccW: pre winter vaccination; mpostVaccW: 
months post winter vaccination, preVaccBI1: pre vaccination with the first dose of the basic immunization 
(Group C only); preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only), 
mpostVaccBI2: months after the second dose of the basic immunization (Group C only); OD: Optical density 
Shades of blue: Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued 
throughout the study; Shades of yellow: Group B (H16, 17, 18, 19), no vaccination history, vaccinated two 
times, six months apart without prior BI; Shades of purple: Group C (H7, 8, 9, 10, 11, 21) no vaccination history, 
BI in summer followed by a booster after six months 
Values between negative line (…….) and positive line (------) are defined as not interpretable results.  
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In the following figures (Fig 13-16) individual serological responses to EHV-4 are shown 
based on vaccination group. 
 
 
3.1.5.2 Group A – Basic immunization > 4 years ago with boosters every 6 months 
In Group A 3/5 (60%) showed a peak two months after the summer vaccination, a similar 
peak was not observed after the winter vaccination. The serological results after the winter 
vaccination appear arbitrary and not associated with the vaccination (Fig. 13). 
 
 
Figure 13: Longitudinal EHV-4 antibody concentrations of horses in Group A (regular pre-
study vaccinations) which received a summer and winter vaccination during the study (n = 5) 
 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; preVaccS: pre summer vaccination; 
mpostVaccS: months post summer vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post 
winter vaccination; OD: Optical density  
Values between negative line (…….) and positive line (------) are defined as not interpretable results.
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3.1.5.3 Group B – no vaccination history, vaccinated twice 6 months apart 
In Group B 2/4 (50%) horses showed a peak in EHV-4 antibodies 2 months after summer 
vaccination. After winter vaccination, 3/4 horses displayed a strong antibody rise (Fig. 14). 
 
 
Figure 14: Longitudinal EHV-4 antibody concentrations of horses in Group B (no pre-study 
vaccinations) which received a summer and winter vaccination during the study (n = 4)
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; preVaccS: pre summer vaccination; 
mpostVaccS: months post summer vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post 
winter vaccination; OD: Optical density  
Values between negative line (…….) and positive line (------) are defined as not interpretable results. 
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3.1.5.4 Group C – no vaccination history, vaccinated with BI followed by a booster 6 months 
later 
In Group C 5/6 (83%) horses showed a peak in the EHV-4 antibodies 1 month after the 
second part of the basic immunization (VaccBI2). In the winter sampling period, only 3 
horses displayed an increase in EHV-4 antibodies 1 month after the vaccination. One of these 
horses (H7) had adverse effects to the first part of the BI (Fig. 15). 
 
 
Figure 15: Longitudinal EHV-4 antibody concentrations of horses in Group C (no pre-study 
vacinations) which received a two-step basic immunization in summer followed by a booster 
in winter (n = 6) 
H: Horse number; VaccBI1: first dose of basic immunization; VaccBI2: second dose of the basic immunization; 
VaccW: winter vaccination; preVaccBI1: pre vaccination with the first dose of the basic immunization; 
preVacBI2: pre vaccination with the second dose of the basic immunization; mpostVaccBI2: months after the 
second dose of the basic immunization; preVaccW: pre winter vaccination; mpostVaccW: months post winter 
vaccination; OD: Optical density  




3.1.4.5 Group D – No vaccination history, natural exposure 
The non-vaccinated horses were seropositive for EHV-4 antibodies over the whole sampling 
period. (Fig. 16). The concentration of EHV-4 antibody titer of the control horses is individual 
and consistent. A reaction to the EHV-1 abortion in the barn is not seen.  
 
 
Figure 16: Longitudinal EHV-4 antibody concentrations of horses in control Group D (no 
pre-study vaccinations; n = 5) which received no vaccinations during the study but may have 
been exposed to virus by an EHV-1 abortion in the same stable.
Horse number; preVaccS: pre summer vaccination; mpostVaccS: months post summer vaccination; preVaccW: 
pre winter vaccination; mpostVaccW: months post winter vaccination; No vaccination history and no 
vaccination as part of the study; natural exposure due to an outbreak occurred in the middle of timepoint 
3mpostVaccS and 4mpostVaccS;  
OD: Optical density  




3.1.6 Viral shedding at pre-study status 
Before the first vaccination 15 horses had samples taken. The samples from the 5 control 
horses were taken at a later timepoint without vaccination. Six swabs from Group A-C and 5 
from group D were available for analysis. In Group D none of the samples taken at the time 
points set as ‘before vaccination’ were positive. From the vaccinated animals 4/6 nasal swabs 
(67%), taken immediately before the first vaccine was administered (VaccS and VaccBI1), 
were positive for EHV-1 and 5/6 (83%) for EHV-4. All five nasal swabs (100%) taken 
immediately before the second step of the BI in Group C were positive for EHV-1 and EHV-
4. Nine out of fifteen nasal swabs (60%) taken before the second vaccine (VaccW) were 
positive for EHV-1 and 10/15 (67%) for EHV-4.  
 
 
3.1.6.1 Contamination of pre-vaccination samples by vaccine vials 
As the high prevalence of viral shedding before vaccination seemed unusual and unlikely, 
contamination of the samples during the sampling procedure was suspected and an 
experiment conducted to test this hypothesis. Vials as well as gloved hands were sampled 
after handling the vaccine vial (see Material and Methods).  
 
The swab taken from the outside of the Duvaxyn vial was positive for EHV-1 and EHV-4. 
One of three swabs (33%) taken from the hands after handling the vaccine vial was positive 
for EHV-4 but all were negative for EHV-1. In contrast, none of the samples taken from the 
Tetanus vaccine vial and hands after handling the vaccine bottle were positive for EHV-1 and 
EHV-4 (Tab. 20). Based on the results of this trial, contamination of the samples taken 
directly before vaccination was suspected as the syringes with the vaccines had been prepared 
prior to taking the pre-vaccination nasal swabs.  
 
These timepoints are therefore not presented in the figures and excluded from discussion 




Table 20: EHV-1 and EHV-4 DNA contamination of the Duvaxyn vaccine bottle and hands 
after handling the vaccine bottle 






Hands before starting the experiment neg neg 
Swab from the outside of a vaccine vial 34.5 31.7 
Hands, after drawing vaccine into the syringe neg 36.9 
Hands, after changing the needle neg neg 
Hands, after removing air from the syringe neg neg 
Vaccine eNAT swab 18.5 16.8 




Hands before starting the experiment neg neg 
Swab from the outside of a vaccine vial neg neg 
Hands, after drawing vaccine into the syringe neg neg 
Hands, after changing the needle neg neg 
Hands, after removing air from the syringe neg neg 
Vaccine eNAT swab neg neg 
Vaccine UTM swab neg neg 
CT: Cycle Threshold; neg: negative; eNAT: nasal swab containing a guanidine-thiocyanate based medium; UTM: 
nasal swab containing a Universal Transport Medium 
 
 
3.1.7 EHV-1 viral shedding after vaccination 
 
3.1.7.1 Viral shedding results of sample groups 
Of the vaccinated horses 8/15 (53%) were positive for EHV-1 at one timepoint after 
vaccination. 
None of the unvaccinated horses were positive for EHV-1 before the EHV-1 abortion in the 
barn occurred, 2/5 (40%) of the horses (H1, H4) were positive for EHV-1 three months after 
the outbreak. One of these horses showed a sustained peak in EHV-1 antibody concentrations 
after the outbreak (see Fig. 10), the other horse did not show an antibody response.  
EHV-1 PCR results based on vaccination group at each time point are shown in Table 21.  
 
Table 21: EHV-1 viral shedding in 21 horses vaccinated against EHV-1/4 with three different 




Timepoint of sampling 
A (n = 5) B (n = 4) C (n = 6) D (n = 5) Total A-C 
(n = 15) 
preVaccS/preVaccBI1 50% (1/2) 67% (2/3) 100% (1/1) 0% (0/5) 67% (4/6) 
1dpostVaccS/1dpostVaccBI1 50% (1/2) 0% (0/3) 0% (0/5) 0% (0/5) 10% (1/10) 
2dpostVaccS/2dpostVaccBI1 0% (0/2) 33% (1/3) 0% (0/5) 0% (0/5) 10% (1/10) 
3dpostVaccS/3dpostVaccBI1 0% (0/2) 0% (0/4) 25% (1/4) 0% (0/5) 10% (1/10) 
4dpostVaccS/4dpostVaccBI1 0% (0/2) 0% (0/4) 0% (0/4) 0% (0/5) 0% (0/10) 
5dpostVaccS/5dpostVaccBI1 0% (0/2) 0% (0/4) 0% (0/4) 0% (0/5) 0% (0/10) 
preVaccBI2   100% (5/5)  100% (5/5) 
1dpostVaccBI2   0% (0/4)  0% (0/4) 
2dpostVaccBI2   20% (1/5)  20% (1/5) 
3dpostVaccBI2   0% (0/5)  0% (0/5) 
4dpostVaccBI2   0% (0/5)  0% (0/5) 
5dpostVaccBI2   40% (2/5)  40% (2/5) 
preVaccW 40% (2/5) 60% (3/4) 67% (4/6) 20% (1/5) 60% (9/15) 
1dpostVaccW 0% (0/5) 33% (1/3) 0% (0/6) 0% (0/5) 7% (1/14) 
2dpostVaccW 0% (0/5) 0% (0/4) 50% (3/6) 20% (1/5) 20% (3/15) 
3dpostVaccW 0% (0/5) 0% (0/4) 0% (0/6) 20% (1/5) 0% (0/15) 
4dpostVaccW 0% (0/5) 25% (1/4) 33% (2/6) 0% (0/5) 20% (3/15) 
5dpostVaccW 0% (0/5) 0% (0/3) 0% (0/6)   0% (0/14) 
preVaccS: pre summer vaccination; dpostVaccS: days post summer vaccination; 
preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); preVacBI2: pre 
vaccination with the second dose of the basic immunization (Group C only); dpostVaccBI1: days after the first 
dose of the basic immunization (Group C only); 
dpostVaccBI2: days after the second dose of the basic immunization (Group C only); 
BI: Basic immunization consisting of two doses given 4 weeks apart; 
Group A: BI >4 years ago, q6months booster which continued throughout the study 
Group B: No vaccination history, vaccinated two times, six months apart without prior BI  
Group C: No vaccination history, BI in summer followed by a booster after six months 
Group D: No vaccination history and no vaccination as part of the study, natural exposure due to an 
outbreak occurred mid-terms between summer and winter sampling period  
Timepoints before each vaccination administration are written in italics  
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3.1.7.2 Viral shedding results of single animals 
Results of nasal shedding from individual horses based on vaccination group before and after 
vaccination are shown in Figure 16.  
 
 
Figure 17: EHV-1 nasal shedding over 5 days in horses vaccinated against EHV-1/4 with 
different protocols (n = 15) 
H: 
Horse number; BI: Basic immunization consisting of two vaccine doses administered 4 weeks apart (VaccBI1, 
VaccBI2); VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer vaccination; 
dpostVaccW: days post winter vaccination; dpostVaccBI1: days after the first dose of the basic immunization 
(Group C only); dpostVaccBI2: days after the second dose of the basic immunization (Group C only); CT: Cycle 
Threshold 
Shades of blue: Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued 
throughout the study; Shades of yellow: Group B (H16, 17, 18, 19), no vaccination history, vaccinated two 
times, six months apart without prior BI; Shades of purple: Group C (H7, 8, 9, 10, 11, 21) no vaccination history, 
BI in summer followed by a booster after six months 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 
positive results include CT-Values < 45. Note overlapping of symbols of individual horses on the x-axis. 
 
 
In the following figures (Fig 18 - 21) nasal shedding of EHV-1 of every horse is shown 
separated by vaccination group.  
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3.1.7.3 Group A – Basic immunization > 4 years ago with boosters every 6 months 
In Group A, only one horse was positive for EHV-1 DNA in the nasal swab one day after 
vaccination (Fig. 18). 
 
 
Figure 18: Longitudinal EHV-1 nasal shedding of horses in Group A (regular pre-study 
vaccinations) which received a summer and winter vaccination during the study (n = 5) 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; CT: Cycle Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.1.7.3 Group B – no vaccination history, vaccinated twice 6 months apart 
In Group B, one horse was EHV-1 positive at three timepoints during the whole sampling 
period. This horse belonged to one of the two of this Group, that displayed a consistent high 
EHV-1 antibody titer over the whole sampling period (Fig. 19). 
 
 
Figure 19: Longitudinal EHV-1 nasal shedding of horses in Group B (no pre-study 
vaccinations) which received a summer and winter vaccination during the study (n = 4) 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; CT: Cycle Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.1.7.5 Group C – no vaccination history, vaccinated with BI followed by a booster 6 months 
later 
In Group C one horse was shedding EVH-1 after the first part of BI. After the second part of 
the BI, three horses were EHV-1 positive. One horse had a high CT-value of 10 at one time 
point, this was the same horse that showed adverse effects after administration of the first part 
of the BI. This horse also showed adequate EHV-1 antibody titers over the whole sampling 
period (Fig. 20). 
 
 
Figure 20: Longitudinal EHV-1 nasal shedding of horses in Group C (no pre-study 
vacinations) which received a two-step basic immunization in summer followed by a booster 
in winter (n = 6)  
H: Horse number; VaccBI1: first dose of basic immunization; VaccBI2: second dose of the basic immunization; 
VaccW: winter vaccination ; dpostVaccBI1: days after the first dose of the basic immunization; dpostVaccBI2: 
days after the second dose of the basic immunization; dpostVaccW: days post winter vaccination; CT: Cycle 
Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.1.7.6 Group D – No vaccination history, natural exposure 
Before natural EHV-1 infection in the control Group occurred, none of the horses were 
shedding EHV-1 virus whereas 14 weeks after EHV-1 abortion in the barn, two horses (H1, 
H4) were shedding EHV-1 at three timepoints (Fig. 21). 
The horse that was shedding EHV-1 at two timepoints (H4) was EHV-1 seropositive during 
the whole Winter sampling period (Fig. 15). The other EHV-1 positive horse (H1) was 
seronegative in the Winter sampling period. 
 
 
Figure 21: Longitudinal EHV-1 nasal shedding of horses in control Group D (no pre-study 
vaccinations; n = 5) which received no vaccinations during the study but may have been 
exposed to virus by an EHV-1 abortion in the same stable. 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; No vaccination history and no vaccination as part of the 
study; natural exposure due to an outbreak occurred mid-terms between summer and winter sampling period; 
CT: Cycle Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 




3.1.8 EHV-4 viral shedding after vaccination 
 
3.1.8.1 Viral shedding results of sample groups 
Ten of fifteen (67%) horses were positive for EHV-4 at one timepoint after vaccination 
(summer or winter or BI1/BI2). One of six (17%) horses of the control Group was positive for 
EHV-4 (H3) at least at one timepoint before natural exposure due to an EHV-1 abortion in the 
barn occurred. After that timepoint, none of the horses of these group were positive for EHV-




Table 22: EHV-4 viral shedding in 20 horses vaccinated against EHV-1/4 with three different 
protocols or sampled as control horses 
EHV-4 
Timepoint of sampling 
A (n = 5) B (n = 4) C (n = 6) D (n = 5) Total A-C 
(n = 15) 
preVaccS/preVaccBI1 50% (1/2) 100% (3/3) 100% (1/1) 0% (0/5) 83% (5/6) 
1dpostVaccS/1dpostVaccBI1 0% (0/2) 0% (0/3) 0% (0/5) 0% (0/5) 0% (0/10) 
2dpostVaccS/2dpostVaccBI1 0% (0/2) 0% (0/3) 0% (0/5) 20% (1/5) 0% (0/10) 
3dpostVaccS/3dpostVaccBI1 0% (0/2) 0% (0/4) 0% (0/4) 0% (0/5) 0% (0/10) 
4dpostVaccS/4dpostVaccBI1 0% (0/2) 50% (2/4) 0% (0/4) 0% (0/5) 20% (2/10) 
5dpostVaccS/5dpostVaccBI1 0% (0/2) 0% (0/4) 0% (0/4) 0% (0/5) 0% (0/10) 
preVaccBI2   100% (5/5)  100% (5/5) 
1dpostVaccBI2   0% (0/4)  0% (0/4) 
2dpostVaccBI2   0% (0/5)  0% (0/5) 
3dpostVaccBI2   0% (0/5)  0% (0/5) 
4dpostVaccBI2   0% (0/5)  0% (0/5) 
5dpostVaccBI2   60% (3/5)  60% (3/5) 
preVaccW 60% (3/5) 75% (3/4) 67% (4/6) 0% (0/5) 67% (10/15) 
1dpostVaccW 0% (0/5) 0% (0/3) 50% (3/6) 0% (0/5) 21% (3/14) 
2dpostVaccW 0% (0/5) 25% (1/4) 33% (2/6) 0% (0/5) 20% (3/15) 
3dpostVaccW 0% (0/5) 50% (2/4) 17% (1/6) 0% (0/5) 20% (3/15) 
4dpostVaccW 20% (1/5) 25% (1/4) 50% (3/6) 0% (0/5) 33% (5/15) 
5dpostVaccW 0% (0/5) 0% (0/3) 0% (0/6)  0% (0/14) 
preVaccS: pre summer vaccination; dpostVaccS: days post summer vaccination; 
preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); preVacBI2: pre 
vaccination with the second dose of the basic immunization (Group C only); dpostVaccBI1: days after the first 
dose of the basic immunization (Group C only); 
dpostVaccBI2: days after the second dose of the basic immunization (Group C only); 
BI: Basic immunization consisting of two doses given 4 weeks apart; 
Group A: BI >4 years ago, q6months booster which continued throughout the study 
Group B: No vaccination history, vaccinated two times, six months apart without prior BI  
Group C: No vaccination history, BI in summer followed by a booster after six months 
Group D: No vaccination history and no vaccination as part of the study, natural exposure due to an 
outbreak occurred mid-terms between summer and winter sampling period  




3.1.8.2 Viral shedding results of single animals 
Overall, EHV-4 shedding after vaccination occurred occasionally. In every vaccination group, 
EHV-4 positive results were detected more frequent after winter vaccination compared to 
summer vaccination or BI immunization. After summer vaccination, 2/15 (13%) horses were 
shedding EHV-4 whereas 7/15 (47%) horses were EHV-4 positive after winter vaccination 
(Fig. 21). Results of nasal shedding from individual horses before and after vaccination of 
every vaccination group are shown in Figure 22.  
 
 
Figure 22: Longitudinal EHV-4 nasal shedding in horses vaccinated against EHV-1/4 with 
different protocols (n = 15) 
 
H: Horse number; BI: Basic immunization consisting of two vaccine doses administered 4 weeks apart 
(VaccBI1, VaccBI2); VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; dpostVaccBI1: days after the first dose of the basic 
immunization (Group C only); dpostVaccBI2: days after the second dose of the basic immunization (Group C 
only); CT: Cycle Threshold 
Shades of blue: Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued 
throughout the study; Shades of yellow: Group B (H16, 17, 18, 19), no vaccination history, vaccinated two 
times, six months apart without prior BI; Shades of purple: Group C (H7, 8, 9, 10, 11, 21) no vaccination history, 
BI in summer followed by a booster after six months 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 
positive results include CT-Values < 45. Note overlapping of symbols of individual horses on the x-axis. 
 
 
In the following figures (Fig. 23-26) nasal shedding of EHV-4 of every horse is shown based 
on vaccination group.   
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3.1.8.3 Group A – Basic immunization > 4 years ago with boosters every 6 months 
In Group A, only one horse was EHV-4 positive in the nasal swab four days after winter 
vaccination (Fig. 23). 
 
 
Figure 23: Longitudinal EHV-4 nasal shedding of horses in group A (regular pre-study 
vaccinations) which received a summer and winter vaccination during the study (n = 5) 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; CT: Cycle Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.1.8.4 Group B – no vaccination history, vaccinated twice 6 months apart 
In Group B, 3/4 (75%) horses were positive for EHV-4 at four different timepoints after 
summer and winter vaccination. One horse was shedding EHV-4 consistently three days in a 
row after winter vaccination (Fig. 24). 
 
 
Figure 24: Longitudinal EHV-4 nasal shedding of horses in Group B (no pre-study 
vaccinations) which received a summer and winter vaccination during the study (n = 4) 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; CT: Cycle Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.1.8.5 Group C – no vaccination history, vaccinated with BI followed by a booster 6 months 
later 
Five of six horses of this group (83%) were EHV-4 positive at least at one sampling 
timepoint. EHV-4 viral shedding increased after administration of every vaccine during the 
sampling period: None of the horses was positive after BI1 whereas 3/6 (50%) of the horses 
(H7, H8, H11) were shedding EHV-4 5 days after administration of BI2. After winter 
vaccination, 4/6 (67%) of the horses were positive for EHV-4 in the nasal swab. One of the 




Figure 25: Longitudinal EHV-4 nasal shedding of horses in Group C (no pre-study 
vacinations) which received a two-step basic immunization in summer followed by a booster 
in winter (n = 6)  
H: Horse number; VaccBI1: first dose of basic immunization; VaccBI2: second dose of the basic immunization; 
VaccW: winter vaccination ; dpostVaccBI1: days after the first dose of the basic immunization; dpostVaccBI2: 
days after the second dose of the basic immunization; dpostVaccW: days post winter vaccination; CT: Cycle 
Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.1.8.6 Group D – No vaccination history, natural exposure 
In the control Group, one horse (H3) was shedding EHV-4 positive at one summer sampling 
timepoint (Fig. 26).  
 
 
Figure 26: Longitudinal EHV-4 nasal shedding of horses in control Group D (no pre-study 
vaccinations; n = 5) which received no vaccinations during the study but may have been 
exposed to virus by an EHV-1 abortion in the same stable. 
H: Horse number; VaccS: summer vaccination; VaccW: winter vaccination; dpostVaccS: days post summer 
vaccination; dpostVaccW: days post winter vaccination; No vaccination history and no vaccination as part of the 
study; natural exposure due to an outbreak occurred mid-terms between summer and winter sampling period; 
CT: Cycle Threshold 
The cut-off for a positive result is CT 45, all negative results are presented on the baseline of the x-axis, all 





3.2 Part B – Screening for equine gamma herpesviruses in healthy horses 
In this study, 59% (40/68) of horses were positive for equine gammaherpesviruses; 38% 
(26/68) were positive for EHV-2, 12% (8/68) for EHV-5 and 9% (6/68) for AHV-5 (Fig. 27). 
 
 
Figure 27: Prevalence of different equine gammaherpesviruses in the tested horses in 
Switzerland 
(n = 68) 
 
Absolute numbers of horses are indicated within the column in parentheses 
 
 
An overview of positive results based on region of origin is shown in Figure 28. In 11/14 
barns, equine gammaherpesviruses were detected. In five barns, every examined horse (TG, 
UR 1, UR 2, VD2, DE 1) was positive for equine gammaherpesviruses. No positive 





Figure 28: Prevalence of equine gammaherpesviruses in 68 horses from 14 different barns 
 
Absolute numbers of horses are indicated within the columns 
 
 
Prevalence of each gammaherpesvirus based on barn of origin is shown in Figure 29. EHV-2 
was present in every barn where at least one gammaherpesvirus positive result was obtained. 
EHV-5 was detected in 6/14 (43%) barns and AHV-5 was found in 3/14 (21%) barns.  
 
 
Figure 29: Distribution of different equine gamma herpesviruses isolated from 68 horses 
from 14 different barns  
 
Absolute numbers of horses are indicated within the column  
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Prevalence of each gammaherpesvirus based on canton of origin is shown in Figure 30. 
Aargau was the only canton in which Gamma Herpesviruses were not detected. In Thurgau 
and Uri all tested horses were positive for at least one gamma herpesvirus. 
 
 
Figure 30: Prevalence of equine herpesviruses referred to the canton and virus-isolate 
 




This study showed that 100% of horses included in the study had antibodies against EHV-4 
irrespective of vaccination status, while only 40% of regularly vaccinated and 25% of 
unvaccinated horses had a positive pre-study status. A transient peak in EHV-4 antibodies 
following summer vaccination and basic immunization was detected, while only a short-lived 
antibody response was seen in approximately 50% of horses after vaccination against EHV-1. 
Viral shedding occurred after vaccination in 53% of horses for EHV -1 and 60% for EHV-4. 
The pre vaccination swab of 80% and 87% of horses was positive for EHV 1 and 4 
respectively due to contamination of the nasal swab with DNA from the vaccine bottle from 
the hands of the researcher. One of the control horses shed EHV-4 at one timepoint.  
 
4.1 PART A – EHV-1 and EHV-4 shedding and antibody response after 
vaccination 
 
4.1.1 EHV-4 Serology 
The high EHV-4 serologic prevalence of 100% in our study population corresponds to 
previous worldwide investigations30,32,86,91 with reported seroprevalences between 80% in 
Turkey32 to 95 – 100 % in Germany,91 Australia86 and New Zealand.30 In our study every 
animal, with or without recent vaccination history, showed a positive EHV-4 antibody titer at 
every timepoint of sampling, even before the first vaccination was administered. EHV-4 is 
suggested to be a commonly found virus in the equine population that horses are likely 
exposed to repeatedly and therefore a strong immune response is mounted. This is supported 
by the results from the analysis of nasal shedding in our study, where one of the horses in the 
control was shedding EV-4 at one time point, despite never receiving a vaccination. 
 
Compared to the control group, a distinct but short-lived EHV-4 antibody peak in all 
vaccination groups was detected after administration of the summer vaccine and after the 
basic immunization. However, besides this peak no distinct influence of the vaccine on EHV-
4 antibody curves was detected and the EHV-4 trajectory of the control group is comparable 
with the vaccination groups. There are few investigations on EHV-4 antibody response to 
vaccination. Measurements of EHV-4 antibody titers in 20 foals after a two-step 
immunization with a combined IWVV (Duvaxyn®EHV-1/4) 4 weeks apart and subsequent 
challenge EHV-4 infection showed induction of EHV-4 antibodies two weeks after first 
vaccination and which were boosted after the second vaccination. However, post vaccination 
titers never reached the concentrations induced after virus challenge.219 A distinct increase in 
EHV-4 antibody titer after booster vaccination could not be detected in our study population. 
Although horses which dropped under the pre-study status at the beginning of winter 
sampling period, showed an increase in EHV-4 antibody titers, this peak was lower compared 
to the summer sampling period. Further investigations are necessary to determine importance 
of a booster vaccination.  
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4.1.2 EHV-1 Serology 
Contrary to the high EHV-4 seroprevalence, EHV-1 antibodies were detected only in 17% of 
horses without a vaccination history at pre-study status. This is similar to other reports were 
seroprevalence in naïve, adult horses was reported to range from 20%30 in New Zealand to 
52% in Turkey.32 Seroprevalence of horses that were regularly vaccinated before this study 
and continued to be vaccinated throughout the study was slightly higher at pre-study status 
(40%) but does not accomplish expectations of an efficient immune response. With respect to 
the small study population, no convincing conclusion on beneficial of regular vaccination is 
possible and further research is needed. Also cellular immunity should also be taken into 
account, not simply the antibody response when considering the effects of a vaccine. We only 
investigated the antibody response in this study. 
 
The EHV-1 antibody response to vaccination was different in every horse but generally low. 
Especially in the group of regularly vaccinated horses, distinct differences in terms of EHV-1 
antibody response were apparent. Only 2/5 of these horses displayed consistent high EHV-1 
antibody concentrations, whereas the other 3 horses did not show an efficient immune 
response. These findings correlate with previous investigations30,32,195. Seroconversion 
following vaccination with an inactivated whole virus EHV-1/4 vaccine (DuvaxynTM, Fort 
Dodge) occurred in less than 30% and 50% of mares and foals, respectively.133 Overall, our 
investigation supports the hypothesis that every horse reacts differently but generally 
moderate to the EHV-1 component of the vaccine and further research is needed.  
 
EHV-1 antibody response to vaccination was moderate in this study. Only horses with pre-
existing antibodies (4 out of 15 from groups A-C) remained EHV-1 antibody positive during 
the whole study and showed clear peaks after vaccination. Of the horses without pre-existing 
antibodies (n = 11) only three became antibody positive after vaccination: One remained 
positive over several timepoints, was negative after 6 months but became positive again after 
the booster (H16, group B). The other two (H9, group C and H23, group A) showed only 
weak positive results at one timepoint (1 month after summer vaccination) before reverting to 
a negative status. Horses with previous vaccination history did not display consistently higher 
EHV-1 antibody concentrations compared to horses not vaccinated before. This moderate 
antibody response after vaccination is in agreement with previous investigations about 
longevity of humoral EHV-1 antibodies after infection.133,192,309 In our study, 8/15 horses 
seroconverted, defined as at least one positive EHV-1 OD value after vaccination. However, 
only 5/15 of the vaccinated horses showed consistent high antibody concentrations during the 
sampling period of six months. This is in agreement with previous investigations, considering 
that the examined horses of these studies did not have a prior vaccination history. No 
comparable investigations following our vaccination protocol is available. A vaccination trial 
with an interval of 60 days did not result in either increased SN-titers or whole EHV-1 ELISA 
values in regularly vaccinated pregnant mares.192 In a different vaccine trials, only a minority 
of vaccinated mares responded with a significant increase in serum antibodies.133 Despite five 
repeated vaccinations over a period of 8 months with an interval of 20, 60, 90 and 60 days, 
antibody and cellular immunity did not always result in increasing immunity.195 Measurement 
of serum antibody response to vaccination is commonly used as an indicator of vaccine 
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efficacy but antibody response alone may not protect against infection. There are case reports 
of clinical EHV-1 infection with a high titer of neutralizing antibodies.52,66  
 
In our study, the response to two different vaccination protocols for horses with no 
vaccination history were evaluated and compared to a group with regular vaccination. Horses 
in the group that received BI followed by a booster had a lower seroprevalence than horses 
vaccinated twice without basic immunization and regularly vaccinated horses. This low 
seroprevalence however has to be interpreted with caution, as our numbers were low and 
results from some horses, particularly in Group C, could not be interpreted as they fell into the 
‘grey zone’ of the test. However, non-interpretable results were obtained in the vaccinated 
groups as frequent as in the control group. Our results are in agreement with another study 
where no significant increase in SN-titers was detected following administration of two 
vaccines 28 days apart in unvaccinated horses.195 The lack of response after the basic 
immunization followed by the booster is particularly discouraging as 50% and 40% of the 
horses were shedding EHV-1 after the second step of the BI and the booster, respectively. 
 
In the regularly vaccinated group, a response to vaccination was seen in 3/5 of animals after 
the first vaccination and 2/5 of horses after the second administration. In one of the animals 
was the antibody response however moderate and only positive at one sampling timepoint 
after summer vaccination. There are few investigations on serological response of horses with 
vaccination history. In addition, these studies include a distinct vaccination protocol of 
pregnant mares on stud farms. However, in a study of Bresgen et al. in 2012,192 both groups of 
mares vaccinated twice with a MLV (5. and 8 month of pregnancy) or three times with a 
IWVV (5., 7. and 9. month of pregnancy) showed moderately increasing antibody 
concentrations with highest concentrations at the time of foaling.192 This is in contrast with 
our low seroconversion rate short lived immune response. 
 
Natural exposure to EHV-1 in the control group resulted in a strong but short-lived antibody 
response in one horse 4 months after the EHV-1 abortion occurred. These results are in 
agreement with prior investigations, that also showed that humoral immunity was only present 
temporarily in most horses after EHV-1 infection.189,190 Whereas virus -neutralizing (VN) 
antibodies are reported to achieve a longer protection up to one year, complement-fixing (CF) 
antibodies only last for three months and show cross reactivity with EHV-4.152 Both antibody 
types are reported to be produced within two weeks after infection152 but EHV-1 reinfection 
with accompanying disease may occur after 3-6 months.102,103 The ELISA used in our study 
detects both VN antibodies as well as CF antibodies.  
 
Interestingly a second horse in the control group showed a strong rise in EHV-1 antibody 
titers which was unrelated to a known exposure. However, this horse did travel to three 
locations at three different places in Switzerland for competition the month before the 
antibody rise. The horse never showed any clinical signs of disease. This is consistent with 
frequent previous observations, reporting seroconversion without clinical signs of upper 
respiratory tract infection in adult horses.9,96 
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One of the vaccinated horses showed an adverse reaction after administration of the first 
vaccine. The observed side effects are in in agreement with the manufacturers reports.310 
Swelling at injection side up to 5cm are very common ( > 1 of 10 treated horses), frequently ( 
> 1 but < 10 of 100 treated horses) accompanied by elevated rectal temperature up to 1.7°C 
for two days after vaccination. Normally, clinical signs resolve without medical treatment. 
However, the horse in our study showed additionally reduced general condition, inappetence 
and stiff gait and was treated for two days with flunixin (Mefosyl®, Zoetis Schweiz GmbH, 
Delémont, Switzerland,1.1 mg/kg SID, IV). These clinical signs, are uncommon ( > 1 but < 
10 of 10’000 treated horses) and medical treatment is recommended by the manufacturer.310 
 
In conclusion we showed that an antibody response to EHV-1 vaccination only occured in 
approximately 8/15 animals, while EHV-4 antibodies were prevalent in the equine population 
irrespective of vaccination. These findings suggest, that generally, the influence of 
vaccination on either EHV-1 and EHV-4 antibody response is moderate. It is likely, that there 
are horses showing a high and possibly as well a prolonged humoral response, defined as 
responders, whilst the non-responders do not show a detectable humoral immune response 
despite regular vaccination. In every Group, irrespective of vaccination, responders and non-
responders were detected, suggesting that either vaccination or natural infection is correlated 
with responder status but immune system and genetics of the individual animal play an 
important role. Interestingly, EHV-1 serological analysis showed much more non-responders 
compared to the high number of EHV-4 responders despite close relationship of these two 
alpha herpesviruses. Further immunological analysis of the horses including determination of 
certain pathways/molecular markers in correlation with EHV-1 specific proteins are necessary 
to detect difference in EHV-1 and EHV-4 responder status. 
 
This part of the study shows the complexity of the immune system and the challenge of 
influencing immunologic pathways by vaccination. Although the small study population does 
not allow representative conclusions, it is likely that immune response against EHV-1 and 
EHV-4 vaccination is still not satisfying. Far more in vitro studies are necessary to understand 
processes of the immune systems to design effective vaccines.  
 
 
4.1.3 Contamination due to DNA presence on outside of vaccine bottles 
An interesting aspect of this study was the detection of EHV DNA on the vaccine bottles and 
hands of the researcher handling these bottles. When results became available it appeared as if 
almost all horses (93%) were shedding virus in their nasal secretions on the day of vaccine 
administration right before the vaccine was administered. As there was no plausible 
explanation for this phenomenon, the authors concluded that contamination of the samples 
must have somehow occurred. The PCR protocols and runs were reviewed, however there 
was no conclusive pattern that could have resulted in contamination of all pre-vaccination 
samples in the laboratory. When reviewing the protocols of the testing days it became evident 
that the vaccine bottles had been handled before the nasal swabs were taken, despite the 
vaccine only being administered after the swab was taken. We then tested the hypothesis of 
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DNA presence on the vaccine bottles that could be transferred to the hands and therefore the 
nasal swabs. 
 
The EHV-vaccine bottle was positive for EHV DNA, the tetanus vaccine bottle used as 
negative control was negative. The measured CT-Values were lower for EHV-4 than for 
EHV-1, implying stronger positivity for EHV-4 compared to EHV-1 in this trial. A possible 
reason might be the larger amount of EHV-4 DNA in the vaccine in comparison to EHV-1 
(Tab. 20). As the qPCR technique is extremely sensitive, handling the vaccine followed by 
taking nasal swabs likely contaminated these samples. Contamination of the hands after 
drawing vaccine in the syringe showed a positive result for EHV-4 but not EHV-1. However, 
accumulation of EHV-1/4 DNA likely occurred by repeating the procedure with multiple vials 
consecutively, which happened during the field trial, but was not tested in this experiment. 
Similar observations have already been made in other studies. Positive nasal swabs on the day 
of vaccination with an Infectious Bovine Rhinotracheitis (IBR) marker vaccine have been 
reported in Belgium (personal communication C. Bachofen, information obtained from a 
meeting of European IBR reference laboratories in Paris, 2020). The contamination was 
verified as the strain detected in the animals was confirmed to be the vaccine strain. As the 
EHV-1,4 vaccine is not a marker vaccine, differentiation of natural and vaccine strains is not 
possible. This problem of potential contamination should be considered when planning future 
experiments and when interpreting results from other studies. 
 
 
4.1.4 EHV-1 and EHV-4 viral shedding after vaccination 
More horses (73%) were shedding EHV-1 and EHV-4 after vaccination compared to the 
control horses before the outbreak (20%). However, qPCR is an extremely sensitive 
technique, detecting smallest amounts of virus DNA.178,303 The detected viral DNA does not 
necessarily confirm the presence of infective virus particles, therefore no conclusion 
regarding replication capacity or infectivity can be made. Several explanations for the virus 
shedding in the vaccination groups are possible: Transportation of the inactivated virions by 
antigen-presenting cells to the nasal mucosa, transmission by cell-to-cell or neuronal 
pathways or reactivation of latent virus infections following vaccination. Differentiation 
between shedding of vaccination-associated inactivated virion particles and reactivation of 
latent EHV infection is performed by cell culture. However, this is not possible in our study 
retrospectively due to the obtained sampling material which cannot be used for cell culture. 
Instead, comparison of the excreted virus sequence with the vaccination strain could be 
attempted, but was not performed. 
 
In contrast to our study, nasal virus shedding following EHV vaccination has been described 
rarely in the past. Studies in bovines investigating excretion of infectious vaccine virions by 
PCR and cell culture after intramuscular (i.m.) vaccination with a glycoprotein E (gE) deleted 
bovine herpesvirus 1 (BoHV-1) strain showed that nasal shedding and subsequent 
transmission to non-vaccinated control animals occurred occasionally.242 Neither in the MLV 
nor in the IWVV group, nasal shedding was observed in calves vaccinated at 3 months of age. 
85 
 
However, in 2-week-old vaccinated calves they detected nasal virus shedding in very low 
titers, but unvaccinated contact calves did not seroconvert. At very low titers in some calves 
that were vaccinated at 2 weeks of age, nasal viral shedding was detected.242 Similar results 
are reported by El-Kholy et al. reporting no nasal virus shedding after i.m. vaccination with a 
live and killed adjuvanted gE negative BoHV-1 mutant in all vaccinated calves.311  
 
A reason for the infrequent detection of viral shedding following vaccination in other studies 
compared to our investigation might be related to the absence of the gE gene in the vaccine 
strain of our study. Several studies have demonstrated the importance of gE for cell-to-cell 
spread in vitro.312 In cell culture, gE-negative alpha herpesvirus strains can only spread by 
passing the extracellular fluid and entering a neighboring cell, which is a less efficient way of 
spreading compared to cell-to-cell spread.312-315 EHV-1 and EHV-4 uses similar glycoproteins 
as other alpha herpesviruses (e.g. herpes simplex virus, HSV; pseudorabies virus, PRV and 
BoHV) to bind to permissive cells and cell-to cell spread.67 The IWVV vaccine used in our 
study contained EHV-1 and EHV-4 strains without viral structural gE deletion and therefore 
cell-to-cell spread may have occurred more efficiently resulting in more frequent nasal virus 
shedding. 
 
Another impact of the viral structural gE is the influence on neuronal spreading. In vivo 
studies showed limited neuronal spread in several hosts for gE-negative strains of PRV and 
HSV.316-318 For BoHV-1, which is hardly microinvasive, difference between spread of wild-
type virus and gE-negative mutant were detected in terms of the amount and duration of virus 
infection in several tissues.319 However, for EHV-1 and EHV-4 predominantly intra-axonal 
transmission is reported to be the most efficient transmission pathway of all transmission 
routes.58 Therefore, neuronal spreading supported by gE might be a reason for the relatively 
frequent virus shedding compared to previous studies.  
 
Our investigations showed that various horses with EHV-1 antibodies at pre-study status had 
positive PCR results in the nasal swabs after vaccination. One of these horses displayed a 
strong positive EHV-1 CT value, too high to suggest relocation of the vaccine strain as a 
cause for the viral shedding. Hence reactivation of latent EHV-1 infection by vaccination is 
suggested in this case. Although the reactivation mechanism of latent virus infection by 
vaccination is unclear, this theory could explain the suggested observation of an increased 
likelihood of EHM development with more frequent vaccination.18,146 None of the horses in 
our study developed clinical signs of upper respiratory tract disease or EHM and therefore no 
conclusion regarding neurological disease and vaccination can be drawn from this study.  
 
Reasons for more frequent EHV-1/4 virus shedding after winter vaccination include seasonal 
aspects such as temperature, time spent indoors, as well as cumulative effects of increased 




There are several limitations of this study, including a small sample size, and the lack of a 
control group as natural EHV-1 infection in the control group occurred. Additionally, results 
of viral shedding before vaccination are lacking due to contamination of the samples with 
DNA from the administered vaccine.Overall, there are no studies available on equine 
herpesvirus detection following vaccination to compare our results to. The assumption of 
repeated vaccination leading to increased virus reactivation and shedding following 
vaccination needs further investigation. In conclusion, vaccination may lead to transient virus 




4.2 Part B – Screening for equine herpesviruses in healthy horses 
Screening for equine herpes viral shedding of 68 sound, adult horses from Switzerland (65) 
and Germany (3) showed frequent shedding of EHV-2. In contrast, other gamma 
herpesviruses, such as EHV-5 and AHV-5 are excreted rarely. Furthermore, none of the 
horses was positive for equine alpha herpesvirus such as EHV-1 or EHV-4.  
 
The high prevalence of EHV-2 is in agreement with other worldwide investigations.257,258 
Reported prevalence of EHV-5 ranges from 0-100%, depending on geographic location, age 
and the investigated specimens.26,262,263 A recent broad prevalence study of herpesviruses 
from the respiratory tract of Polish horses recorded 80% equine herpesvirus positive results in 
nasal swabs of more than 500 sound horses.258  
 
EHV-5 and EHV-2 were found more often in horses with lower airway inflammation 
compared to healthy horses in prior studies.26,142,264 Investigations, considering correlation of 
equine gamma herpesviruses and clinical disease suggest, that EHV-2 likely induces or 
predisposes equids to respiratory disease.26 Horses shedding EHV-2 were three times more 
likely to display clinical respiratory disease compared to non shedders.26 The asinine 
herpesviruses AHV-4, AHV-5 and AHV-6 have been detected in donkeys with interstitial 
pneumonia, with lesions similar to EMPF.243,299 AHV-5 in horses was reported with 
respiratory disorders or “poor performance syndrome”246 as well as in two EMPF case reports 
with concurrent EHV-5 infection.283 To the authors knowledge, there are no previous studies 
investigating range and frequency of equine gamma herpesviruses shedding in Switzerland. 
 
In our study population, only gamma herpesviruses were detected, no alpha or beta herpes 
viruses were detected. This is not due to the method used, as panherpes Nested PCR is a 
sensitive technique to identify a broad range of herpesviruses, including alfa-, beta- and 
gamma herpesviruses. This method targets for a highly conserved region of the herpesviral 
DNA polymerase gene. Using degenerate consensus primers, PCR is able to not only detect 
known herpes viruses, but also novel herpesviruses without information on DNA sequence.305 
However, sequencing of PCR products is impaired by small amount of present virus. 
Therefore, incomplete reads and incorrect incorporation of bases by Taq DNA polymerase 
may occur.305 Co-infections may often be overlooked as only the sequence of the dominant 
virus will be identified in a panherpesvirus PCR. Superimposed sequences and double peaks 
in electropherograms are indications for co-infections.320 In our study, coinfections of gamma 
herpesviruses with small amounts of alpha herpesviruses can therefore not be ruled out. 
 
In our study, coinfections, predominately EHV-2 and EHV-5, were shown in approximately 
35% (14/40) of positive sequences. In this investigation, every positive result was assessed 
visually in an electropherogram viewer regarding likelihood of coinfection. Sequences 
supposed to include coinfection by electropherogram assessment were examined additionally 
by an alignment for illustration in the SeqMan Pro program (Fig. 30). Therefore, this study 
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only gives an estimation on equine herpesvirus coinfections. More precise investigations 




Figure 30: Exemplary demonstration of EHV-2 with EHV-5 coinfection in samples examined 
by panherpes nested PCR of four sequences
 
Insert: alignment of the sequences with suspected coinfection due to double peaks in the electropherogram. On 
top, EHV-2 sequence without coinfection, followed by coinfection of EHV-5 with EHV-2 (blue arrows) and 
EHV-2 with either EHV-5 or AHV-5 infection (orange arrow) are presented. 
 
 
Our results are in agreement with previous prevalence investigations in other countries. For 
example in turkey, coinfection with EHV-2 and EHV-5 occurred in 45% of examined 
samples.257 In New Zealand coinfection with multiple herpesviruses (EHV-1, -2, -4, -5) in 
more than 50% of the virus-positive tested horses was shown.142 Detection rates of co-
infection vary depending on sampling site. A considerably lower coinfection rates of 5% in 
bronchoalveolar fluid (BALF) samples of horses with respiratory disease were reported in a 
recent study in Ethiopia.26 EHV-5 is the suggested primary causative agent of Equine 
Multinodular Pulmonary Fibrosis (EMPF). However all gamma herpesviruses have the 
potential for inducing fibrosis and coinfection with EHV-2 and AHV-5 has been reported in 




Although the sampled population is not fully representative for the entire Swiss horse 
population, a first insight into the prevalence of equine gamma herpesviruses in Switzerland 
was obtained. It appears as if horses in Switzerland shed a similar range of equine gamma 
herpesviruses compared to reports from other countries. Also the prevalence of shedding 
appears similar to other countries. Further investigations including a larger sample size as 
well as longitudinal sampling of individual horses are necessary to obtain more information 
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Table 18a: Overview of all available samples from every horse (H1-H24) 
Sample Timepoint of 
Sampling 
H1 H2 H3 H4 H5 H6 H7 H8 
S preVaccS/ 
preVaccBI1 
x x x x x x x x 
S preVaccBI2       x x 
S 1mpostVaccS/ 
1mpostVaccBI2 
x x x x x x x x 
S 2mpostVaccS/ 
2mpostVaccBI2 
x x x x x x x x 
S 3mpostVaccS/ 
3mpostVaccBI2 
x x x x x x x x 
S 4mpostVaccS 
4mpostVaccBI2 
x x x x x x x x 
S 5mpostVaccS 
5mpostVaccBI2 
x x x x x x x x 
S preVaccW       x x 
S 1mpostVaccW x x x x  x x x 
S 2mpostVaccW x x x x  x x x 
S 3mpostVaccW x x x x  x x x 
S 4mpostVaccW x x x x  x x x 
S 5mpostVaccW x x x x  x x x 
NS preVaccS/ 
preVaccBI1 
x x x x x x   
NS 1dpostVaccS/ 
1dpostVaccBI1 
x x x x x x x x 
NS 2dpostVaccS/ 
2dpostVaccBI1 
x x x x x x x x 
NS 3dpostVaccS/ 
3dpostVaccBI1 
x x x x x x x  
NS 4dpostVaccS/ 
4dpostVaccBI1 
x x x x x x x  
NS 5dpostVaccS/ 
5dpostVaccBI1 




Sample Timepoint of 
Sampling 
H1 H2 H3 H4 H5 H6 H7 H8 
NS preVaccBI2       x x 
NS 1dpostVaccBI2       x x 
NS 2dpostVaccBI2       x x 
NS 3dpostVaccBI2       x x 
NS 4dpostVaccBI2       x  
NS 5dpostVaccBI2       x x 
NS preVaccW x x x x  x x x 
NS 1dpostVaccW x x x x  x x x 
NS 2dpostVaccW x x x x  x x x 
NS 3dpostVaccW x x x x  x x x 
NS 4dpostVaccW x x x x  x x x 
NS 5dpostVaccW       x x 
 Total S 11 11 11 11 6 11 13 13 
 Total NS 11 11 11 11 6 11 17 13 
 
Table 18b: Overview of all available samples from every horse (H9-H16) 
Sample Timepoint of 
Sampling 
H9 H10 H11 H12 H13 H14 H15 H16 
S preVaccS/ 
preVaccBI1 
x x x x x x x x 
S preVaccBI2 x x x      
S 1mpostVaccS/ 
1mpostVaccBI2 
x x x x x x  x 
S 2mpostVaccS/ 
2mpostVaccBI2 
x x x x x x  x 
S 3mpostVaccS/ 
3mpostVaccBI2 
x x x x x x  x 
S 4mpostVaccS 
4mpostVaccBI2 
x x x x x x x x 
S 5mpostVaccS 
5mpostVaccBI2 




Sample Timepoint of 
Sampling 
H9 H10 H11 H12 H13 H14 H15 H16 
S preVaccW x x x x x x  x 
S 1mpostVaccW x x x x x x  x 
S 2mpostVaccW x x x x x x  x 
S 3mpostVaccW x x x x x x  x 
S 4mpostVaccW x x x x x x  x 
S 5mpostVaccW x x x x x x  x 
NS preVaccS/ 
preVaccBI1 
  x       x 
NS 1dpostVaccS/ 
1dpostVaccBI1 
x x x     x 
NS 2dpostVaccS/ 
2dpostVaccBI1 
x x x    x x 
NS 3dpostVaccS/ 
3dpostVaccBI1 
x x x    x x 
NS 4dpostVaccS/ 
4dpostVaccBI1 
x x x     x 
NS 5dpostVaccS/ 
5dpostVaccBI1 
x x x     x 
NS preVaccBI2 x x x      
NS 1dpostVaccBI2 x x x      
NS 2dpostVaccBI2 x x x      
NS 3dpostVaccBI2 x x x      
NS 4dpostVaccBI2 x x x      
NS 5dpostVaccBI2 x x x      
NS preVaccW x x x x x x x x 
NS 1dpostVaccW x x x x x x  x 
NS 2dpostVaccW x x x x x x  x 
NS 3dpostVaccW x x x x x x  x 
NS 4dpostVaccW x x x x x x  x 




Sample Timepoint of 
Sampling 
H9 H10 H11 H12 H13 H14 H15 H16 
 Total S 13 13 13 12 12 12 3 12 
 Total NS 17 18 17 6 6 6 3 12 
 
Table 18c: Overview of all available samples from every horse (H17-H24) 
Sample Timepoint of 
Sampling 
H17 H18 H19 H20 H21 H22 H23 H24 Total 
S preVaccS/ 
preVaccBI1 
x x x x x x x x 24/24 
S preVaccBI2     x    6/7 
S 1mpostVaccS/ 
1mpostVaccBI2 
x x x x x x x x 23/24 
S 2mpostVaccS/ 
2mpostVaccBI2 
x x x x x x x x 23/24 
S 3mpostVaccS/ 
3mpostVaccBI2 
x  x x x x x   21/24 
S 4mpostVaccS 
4mpostVaccBI2 
x x x x x x x   23/24 
S 5mpostVaccS 
5mpostVaccBI2 
x x x x x x x   23/24 
S preVaccW x x x   x x x   15/24 
S 1mpostVaccW x x x   x x x   20/24 
S 2mpostVaccW x x x   x x x   20/24 
S 3mpostVaccW x x x   x x x   20/24 
S 4mpostVaccW x x x   x x x   20/24 
S 5mpostVaccW x x x   x x x   20/24 
NS preVaccS/ 
preVaccBI1 
x x     x x x 13/24 
NS 1dpostVaccS/ 
1dpostVaccBI1 
x  x x  x x x 18/24 
NS 2dpostVaccS/ 
2dpostVaccBI1 
x  x x  x x x 19/24 
NS 3dpostVaccS/ 
3dpostVaccBI1 




Sample Timepoint of 
Sampling 
H17 H18 H19 H20 H21 H22 H23 H24 Total 
NS 4dpostVaccS/ 
4dpostVaccBI1 
x x x x  x x x 18/24 
NS 5dpostVaccS/ 
5dpostVaccBI1 
x x x x  x x x 18/24 
NS preVaccBI2    x     6/7 
NS 1dpostVaccBI2    x     6/7 
NS 2dpostVaccBI2    x     6/7 
NS 3dpostVaccBI2    x     6/7 
NS 4dpostVaccBI2    x     5/7 
NS 5dpostVaccBI2    x     6/7 
NS preVaccW x x x   x x x   21/24 
NS 1dpostVaccW x  x   x x x   19/24 
NS 2dpostVaccW x x x   x x x   20/24 
NS 3dpostVaccW x x x   x x x   20/24 
NS 4dpostVaccW x x x   x x x   20/24 
NS 5dpostVaccW  x x   x x x   14/24 
 Total S 12 11 12 6 13 12 12 3  
 Total NS 11 9 11 11 6 12 12 6  
Table 18a-c: H: horse number; S: serum sample; NS: nasal swab; x: taken sample;  
Group A-C: vaccination Groups; Group D: control Group 
Group A (H12, 13, 14, 22, 23); Group B (H16, 17, 18, 19); Group C (H7, 8, 9, 10, 11, 21); 
Group D: (H1, H2, H3, H4, H5, H6) 
preVaccS: pre summer vaccination; mpostVaccS: months post summer vaccination; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); 
preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only); 
mpostVaccBI1: months after the first dose of the basic immunization (Group C only); 
mpostVaccBI2: months after the second dose of the basic immunization (Group C only); 
BI: Basic immunization consisting of two doses given 4 weeks apart 
Total: all taken samples of every sampling timepoint referred to the total of all sampled horses  
Total S: all taken serum samples referred to every horse; 




Data Tables in OD-Values corresponding to Fig. 7 (Group A-C): Longitudinal EHV-1 antibody 
concentrations in horses vaccinated against EHV-1/4 with different protocols (n = 15) 
 
 H16 H17 H18 H19 H21 H22 H23 
preVaccS/preVaccBI1 0.12 0.87 0.03 0.05 0.02 0.00 0.01 
preVaccBI2     0.03   
1mpostVaccS/1mpostVaccBI2 0.50 0.88 0.05 0.08 0.11 0.01 0.25 
2mpostVaccS/2mpostVaccBI2 0.50 1.11 0.02 0.11 0.04 0.00 0.00 
3mpostVaccS/3mpostVaccBI2 0.39 0.69  0.07 0.03 0.00 0.01 
4mpostVaccS/4mpostVaccBI2 0.42 0.71 0.04 0.05 0.01 0.00 0.01 
5mpostVaccS/5mpostVaccBI2 0.35 0.64 0.02 0.03 0.06 0.00 0.00 
preVaccW 0.09 0.37 0.01 0.09 0.06 0.00 0.01 
1mpostVaccW 0.34 0.84 0.07 0.09 0.01 0.00 0.00 
2mpostVaccW 0.31 0.70 0.03 0.08 0.03 0.00 0.01 
3mpostVaccW 0.47 0.76 0.04 0.07 0.05 0.01 0.00 
4mpostVaccW 0.38 0.76 0.05 0.10 0.03 0.00 0.02 
5mpostVaccW 0.32 0.94 0.02 0.07 0.00 0.01 0.01 
H: Horse number; OD: Optical density; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccS: pre summer vaccination; mpostVaccS: months post summer vaccination; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); 
preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only); 
mpostVaccBI2: months after the second dose of the basic immunization (Group C only) 
Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued throughout the study; 
Group B (H16, 17, 18, 19), no vaccination history, vaccinated two times, six months apart without prior BI; 
Group C (H7, 8, 9, 10, 11, 21) no vaccination history, BI in summer followed by a booster after six months 
positive results: > 0.2; negative results: < 0.1; non-interpretable results: 0.1 – 0.2  
 H7 H8 H9 H10 H11 H12 H13 H14 
preVaccS/preVaccBI1 0.67 0.00 0.00 0.05 0.02 0.4 0.76 0.05 
preVaccBI2 0.60 0.00 0.11 0.02 0.00    
1mpostVaccS/1mpostVaccBI2 0.97 0.02 0.43 0.10 0.00 0.6 0.88 0.03 
2mpostVaccS/2mpostVaccBI2 0.50 0.02 0.15 0.05 0.01 0.73 1.19 0.02 
3mpostVaccS/3mpostVaccBI2 0.55 0.00 0.12 0.05 0.00 0.44 0.80 0.04 
4mpostVaccS/4mpostVaccBI2 0.54 0.00 0.09 0.03 0.00 0.31 0.94 0.02 
5mpostVaccS/5mpostVaccBI2 0.42 0.00 0.00 0.26 0.00 0.29 0.93 0.01 
preVaccW 0.12 0.00 0.08 0.02 0.00 0.28 0.94 0.02 
1mpostVaccW 0.51 0.01 0.20 0.10 0.02 0.69 0.93 0.02 
2mpostVaccW 0.87 0.03 0.15 0.05 0.00 0.35 1.16 0.00 
3mpostVaccW 0.55 0.09 0.15 0.14 0.00 0.54 1.34 0.01 
4mpostVaccW 0.56 0.00 0.10 0.07 0.04 0.22 1.04 0.07 
5mpostVaccW 0.55 0.05 0.04 0.03 0.00 0.48 1.01 0.01 
112 
 
OD-Values corresponding to Fig. 8 (Group A): Longitudinal EHV-1 antibody concentrations in horses 
vaccinated against EHV-1 with a basic immunization >4 years ago with regular boosters every 6 months 
including summer and winter during the study (n = 5) 
 H12 H13 H14 H22 H23 
preVaccS 0.4 0.76 0.05 0.00 0.01 
1mpostVaccS 0.6 0.88 0.03 0.01 0.25 
2mpostVaccS 0.73 1.19 0.02 0.00 0.00 
3mpostVaccS 0.44 0.80 0.04 0.00 0.01 
4mpostVaccS 0.31 0.94 0.02 0.00 0.01 
5mpostVaccS 0.29 0.93 0.01 0.00 0.00 
preVaccW 0.28 0.94 0.02 0.00 0.01 
1mpostVaccW 0.69 0.93 0.02 0.00 0.00 
2mpostVaccW 0.35 1.16 0.00 0.00 0.01 
3mpostVaccW 0.54 1.34 0.01 0.01 0.00 
4mpostVaccW 0.22 1.04 0.07 0.00 0.02 
5mpostVaccW 0.48 1.01 0.01 0.01 0.01 
H: Horse number; OD: Optical density: preVaccS: pre summer vaccination; mpostVaccS: months post summer 
vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 
positive results: > 0.2; negative results: < 0.1; non-interpretable results: 0.1 – 0.2 
 
 
OD- Values corresponding to Fig. 9 (Group B): Longitudinal EHV-1 antibody concentrations in horses with 
no EHV-1 vaccination history which were vaccinated twice 6 months apart in summer and winter during the 
study (n = 4) 
 H16 H17 H18 H19 
preVaccS 0.12 0.87 0.03 0.05 
1mpostVaccS 0.50 0.88 0.05 0.08 
2mpostVaccS 0.50 1.11 0.02 0.11 
3mpostVaccS 0.39 0.69  0.07 
4mpostVaccS 0.42 0.71 0.04 0.05 
5mpostVaccS 0.35 0.64 0.02 0.03 
preVaccW 0.10 0.37 0.01 0.09 
1mpostVaccW 0.34 0.84 0.07 0.09 
2mpostVaccW 0.31 0.70 0.03 0.08 
3mpostVaccW 0.47 0.76 0.04 0.07 
4mpostVaccW 0.38 0.76 0.05 0.10 
5mpostVaccW 0.32 0.94 0.02 0.07 
Horse number; OD: Optical density: preVaccS: pre summer vaccination; mpostVaccS: months post summer 
vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination 
positive results: > 0.2; negative results: < 0.1; non-interpretable results: 0.1 – 0.2 
113 
 
OD-Values corresponding to Fig. 10 (Group C): Longitudinal EHV-1 antibody concentrations in horses with 
no EHV-1 vacination history which received a basic immunization in summer (2 doses 4 weeks apart) followed 
by a booster vaccine 6 months later, in winter (n = 6) 
 H7 H8 H9 H10 H11 H21 
preVaccBI1 0.67 0.00 0.00 0.05 0.02 0.02 
preVaccBI2 0.60 0.00 0.11 0.02 0.00 0.03 
1mpostVaccBI2 0.97 0.02 0.43 0.10 0.00 0.11 
2mpostVaccBI2 0.50 0.02 0.15 0.05 0.01 0.04 
3mpostVaccBI2 0.55 0.00 0.12 0.05 0.00 0.03 
4mpostVaccBI2 0.54 0.00 0.09 0.03 0.00 0.01 
5mpostVaccBI2 0.42 0.00 0.00 0.26 0.00 0.06 
preVaccW 0.12 0.00 0.08 0.02 0.00 0.06 
1mpostVaccW 0.51 0.01 0.20 0.10 0.02 0.01 
2mpostVaccW 0.87 0.03 0.15 0.05 0.00 0.03 
3mpostVaccW 0.55 0.09 0.15 0.14 0.00 0.05 
4mpostVaccW 0.56 0.00 0.10 0.07 0.04 0.03 
5mpostVaccW 0.55 0.05 0.04 0.03 0.00 0.00 
H: Horse number; OD: Optical density; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccBI1: pre vaccination with the first dose of the basic immunization; preVacBI2: pre vaccination with the 
second dose of the basic immunization; mpostVaccBI2: months after the second dose of the basic immunization; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 




OD-Values corresponding to Fig. 11: Longitudinal EHV-1 antibody concentrations in control Group D  
(n = 5) 
 H1 H2 H3 H4 H6 
preVaccS 0.00 0.03 0.15 0.25 0.01 
1mpostVaccS 0.00 0.15 0.37 0.39 0.00 
2mpostVaccS 0.00 0.00 0.13 0.13 0.00 
3mpostVaccS 0.45 0.02 0.14 0.50 0.04 
4mpostVaccS 0.17 0.05 0.15 1.72 0.38 











1mpostVaccW 0.00 0.00 0.04 1.27 0.11 
2mpostVaccW 0.06 0.03 1.11 0.73 0.14 
3mpostVaccW 0.05 0.01 0.85 0.67 0.02 
4mpostVaccW 0.03 0.03 0.79 0.50 0.11 
5mpostVaccW 0.04 0.02 0.68 0.42 0.16 
H: Horse number; OD: Optical density; preVaccS: pre summer vaccination; mpostVaccS: months post summer 
vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; No vaccination 
history and no vaccination as part of the study; natural exposure due to an outbreak occurred in the middle of 
timepoint 3mpostVaccS and 4mpostVaccS; positive results: > 0.2; negative results: < 0.1; non-interpretable  
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OD-Values corresponding to Fig. 12 (Group A-C): Longitudinal EHV-4 antibody concentrations in horses 
vaccinated against EHV-1/4 with different protocols (n = 15) 
 
 H16 H17 H18 H19 H21 H22 H23 
preVaccS/preVaccBI1 1.20 1.86 1.46 2.16 0.98 2.29 1.95 
preVaccBI2     1.10   
1mpostVaccS/1mpostVaccBI2 1.52 2.53 1.55 2.46 1.34 2.27 2.00 
2mpostVaccS/2mpostVaccBI2 1.61 2.83 1.20 2.96 1.02 2.15 2.79 
3mpostVaccS/3mpostVaccBI2 1.37 2.09  2.25 1.01 1.97 1.90 
4mpostVaccS/4mpostVaccBI2 1.54 2.01 1.51 2.19 0.91 2.21 1.93 
5mpostVaccS/5mpostVaccBI2 1.35 1.93 1.14 2.09 0.84 1.95 1.78 
preVaccW/preW 0.41 1.42 1.13 2.28 1.03 1.49 1.99 
1mpostVaccW 1.61 2.14 1.93 2.16 0.89 2.08 1.79 
2mpostVaccW 1.46 2.08 1.45 2.22 1.15 1.96 2.04 
3mpostVaccW 1.78 2.08 1.78 2.21 1.25 2.64 1.86 
4mpostVaccW 1.68 2.03 1.55 2.42 1.14 2.61 2.26 
5mpostVaccW 1.53 2.30 1.49 2.36 0.59 2.31 2.09 
H: Horse number; OD: Optical density; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccS: pre summer vaccination; mpostVaccS: months post summer vaccination; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); 
preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only); 
mpostVaccBI2: months after the second dose of the basic immunization (Group C only) 
Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued throughout the study; 
Group B (H16, 17, 18, 19), no vaccination history, vaccinated two times, six months apart without prior BI; 
Group C (H7, 8, 9, 10, 11, 21) no vaccination history, BI in summer followed by a booster after six months 
Group D: No vaccination history and no vaccination as part of the study, natural exposure due to an 
positive results: > 0.2; negative results: < 0.1; non-interpretable results: 0.1 – 0.2  
 H7 H8 H9 H10 H11 H12 H13 H14 
preVaccS/preVaccBI1 2.37 1.30 1.34 1.36 1.77 2.06 2.00 1.76 
preVaccBI2 2.28 0.62 1.40 0.35 1.92    
1mpostVaccS/1mpostVaccBI2 3.03 2.92 2.07 1.90 2.62 2.11 1.61 1.81 
2mpostVaccS/2mpostVaccBI2 2.22 2.00 1.53 1.32 1.73 2.85 2.90 1.64 
3mpostVaccS/3mpostVaccBI2 2.24 1.80 1.62 1.07 1.67 1.86 2.12 1.74 
4mpostVaccS/4mpostVaccBI2 2.29 1.83 1.56 1.03 1.80 1.89 1.97 1.67 
5mpostVaccS/5mpostVaccBI2 2.22 1.48 1.16 0.70 1.75 1.85 2.05 1.60 
preVaccW 0.64 1.65 1.11 0.30 1.79 1.63 2.16 1.50 
1mpostVaccW 2.26 1.63 1.29 1.44 1.77 2.10 2.06 1.94 
2mpostVaccW 2.47 2.76 1.45 1.32 1.49 2.15 2.37 1.36 
3mpostVaccW 2.44 1.57 1.77 1.63 1.86 2.17 2.39 1.56 
4mpostVaccW 2.40 1.57 1.60 1.47 1.82 1.78 2.20 2.01 
5mpostVaccW 2.44 1.56 1.39 1.32 1.71 2.27 2.32 1.92 
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OD-Values corresponding to Fig. 13 (Group A): Longitudinal EHV-4 antibody concentrations in horses 
vaccinated against EHV-4 with a basic immunization >4 years ago with regular boosters every 6 months 
including summer and winter during the study (n = 5) 
 H12 H13 H14 H22 H23 
preVaccS 2.06 2.00 1.76 2.29 1.95 
1mpostVaccS 2.11 1.61 1.81 2.27 2.00 
2mpostVaccS 2.85 2.90 1.64 2.15 2.79 
3mpostVaccS 1.86 2.12 1.74 1.97 1.90 
4mpostVaccS 1.89 1.97 1.67 2.21 1.93 
5mpostVaccS 1.85 2.05 1.60 1.95 1.78 
preVaccW 1.63 2.16 1.50 1.49 1.99 
1mpostVaccW 2.10 2.06 1.94 2.08 1.79 
2mpostVaccW 2.15 2.37 1.36 1.96 2.04 
3mpostVaccW 2.17 2.39 1.56 2.64 1.86 
4mpostVaccW 1.78 2.20 2.01 2.61 2.26 
5mpostVaccW 2.27 2.32 1.92 2.31 2.09 
H: Horse number; OD: Optical density: preVaccS: pre summer vaccination; mpostVaccS: months post summer 
vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 
positive results: > 0.2; negative results: < 0.1; non-interpretable results: 0.1 – 0.2 
 
 
OD-Values corresponding to Fig. 14 (Group B): Longitudinal EHV-4 antibody concentrations in horses with 
no EHV-4 vaccination history which were vaccinated twice 6 months apart in summer and winter during the 
study (n = 4) 
 H16 H17 H18 H19 
preVaccS 1.20 1.86 1.46 2.16 
1mpostVaccS 1.52 2.53 1.55 2.46 
2mpostVaccS 1.61 2.83 1.20 2.96 
3mpostVaccS 1.37 2.09  2.25 
4mpostVaccS 1.54 2.01 1.51 2.19 
5mpostVaccS 1.35 1.93 1.14 2.09 
preVaccW 0.41 1.42 1.13 2.28 
1mpostVaccW 1.61 2.14 1.93 2.16 
2mpostVaccW 1.46 2.08 1.45 2.22 
3mpostVaccW 1.78 2.08 1.78 2.21 
4mpostVaccW 1.68 2.03 1.55 2.42 
5mpostVaccW 1.53 2.30 1.49 2.36 
H: Horse number; OD: Optical density: preVaccS: pre summer vaccination; mpostVaccS: months post summer 
vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 




OD-Values corresponding to Fig. 15 (Group C): Longitudinal EHV-4 antibody concentrations in horses with 
no EHV-4 vacination history which received a basic immunization in summer (2 doses 4 weeks apart) followed 
by a booster vaccine 6 months later, in winter (n = 6) 





1.36 1.77 0.98 
preVaccBI2 2.28 0.62 1.40 0.35 1.92 1.10 
1mpostVaccBI2 3.03 2.92 2.07 1.90 2.62 1.34 
2mpostVaccBI2 2.22 2.00 1.53 1.32 1.73 1.02 
3mpostVaccBI2 2.24 1.80 1.62 1.07 1.67 1.01 





0.70 1.75 0.84 
preVaccW 0.64 1.65 1.11 0.30 1.79 1.03 
1mpostVaccW 2.26 1.63 1.29 1.44 1.77 0.89 
2mpostVaccW 2.47 2.76 1.45 1.32 1.49 1.15 
3mpostVaccW 2.44 1.57 1.77 1.63 1.86 1.25 
4mpostVaccW 2.40 1.57 1.60 1.47 1.82 1.14 
5mpostVaccW 2.44 1.56 1.39 1.32 1.71 0.59 
H: Horse number; OD: Optical density; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccBI1: pre vaccination with the first dose of the basic immunization; preVacBI2: pre vaccination with the 
second dose of the basic immunization; mpostVaccBI2: months after the second dose of the basic immunization; 
preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; 




OD-Values corresponding to Fig. 16: Longitudinal EHV-4 antibody concentrations in control Group D 
(n = 5) 
 H1 H2 H3 H4 H6 
preVaccS 1.66 1.22 1.63 1.46 1.80 
1mpostVaccS 1.42 1.62 1.92 1.34 1.64 
2mpostVaccS 1.63 1.25 1.57 1.47 1.73 
3mpostVaccS 1.74 1.01 1.55 1.31 1.84 
4mpostVaccS 1.62 0.94 1.48 1.37 1.80 











1mpostVaccW 1.45 1.13 1.64 1.75 1.69 
2mpostVaccW 1.85 0.94 1.79 1.41 1.69 
3mpostVaccW 1.69 1.06 1.86 1.42 1.76 
4mpostVaccW 1.50 1.40 1.75 1.52 1.68 
5mpostVaccW 1.56 1.27 1.88 1.41 1.87 
H: Horse number; OD: Optical density; preVaccS: pre summer vaccination; mpostVaccS: months post summer 
vaccination; preVaccW: pre winter vaccination; mpostVaccW: months post winter vaccination; No vaccination 
history and no vaccination as part of the study; natural exposure due to an outbreak occurred in the middle of 
timepoint 3mpostVaccS and 4mpostVaccS; positive results: > 0.2; negative results: < 0.1; non-interpretable 




CT-Values corresponding to Fig. 17 (Group A-C): EHV-1 nasal shedding over 5 days in horses vaccinated 
against EHV-1/4 with different protocols (n = 15) 



















































preVaccBI2 28.98 32.93 33.93 34.11 34.54    
1dpostVaccBI2 45.00 45.00 45.00 45.00 45.00    
2dpostVaccBI2 45.00 45.00 45.00 45.00 36.34    
3dpostVaccBI2 45.00 45.00 45.00 45.00 45.00    
4dpostVaccBI2 45.00  45.00 45.00 45.00    
5dpostVaccBI2 43.70 35.82 45.00 45.00 45.00    
preVaccW 45.00 27.56 31.95 27.92 31.80 43.19 34.47 45.00 
1dpostVaccW 45.00 45.00 45.00 45.00 43.19 45.00 45.00 45.00 
2dpostVaccW 09.91 36.29 36.10 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 45.00 36.90 36.78 45.00 45.00 45.00 45.00 





 H16 H17 H18 H19 H21 H22 H23 
preVaccS/preVaccBI1 35.04 45.00 36.78  Missing 
sample 
45.00 32.55 












45.00 45.00 45.00 45.00 Missing 
sample 
45.00 45.00 





45.00 45.00 45.00 45.00 Missing 
sample 
45.00 45.00 

























    Missing 
sample 
  
preVaccW 34.81 36.72 45.00 36.90 45.00 45.00 45.00 
1dpostVaccW 45.00 37.06   45.00 45.00 45.00 
2dpostVaccW 45.00 45.00 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 38.75 45.00 45.00 45.00 45.00 45.00 
5dpostVaccW 45.00  45.00 45.00 45.00 45.00 45.00 
H: Horse number; CT: Cyclic Treshold; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccS: pre summer vaccination; dpostVaccS: days post summer vaccination; 
preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); 
preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only); 
dpostVaccBI1: days after the first dose of the basic immunization (Group C only) 
dpostVaccBI2: days after the second dose of the basic immunization (Group C only) 
Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued throughout the study; 
Group B (H16, 17, 18, 19), no vaccination history, vaccinated two times, six months apart without prior BI; 
Group C (H7, 8, 9, 10, 11, 21) no vaccination history, BI in summer followed by a booster after six months 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 18 (Group A): Longitudinal EHV-1 nasal shedding in horses vaccinated 
against EHV-1 with a basic immunization >4 years ago with regular boosters every 6 months including summer 
and winter during the study (n = 5) 











































preVaccW 43.19 34.47 45.00 45.00 45.00 
1dpostVaccW 45.00 45.00 45.00 45.00 45.00 
2dpostVaccW 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 45.00 45.00 45.00 45.00 
5dpostVaccW 45.00 45.00 45.00 45.00 45.00 
H: Horse number; CT: Cyclic Treshold; preVaccS: pre summer vaccination; dpostVaccS: days post summer 
vaccination; preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 19 (Group B): Longitudinal EHV-1 nasal shedding in horses with no 
vaccination history against EHV-1 and vaccinated twice 6 months apart in summer and winter during the study 
(n = 4) 
 H16 H17 H18 H19 
preVaccS 35.04 45.00 36.78  
1dpostVaccS 45.00 45.00  45.00 
2dpostVaccS 45.00 38.91  45.00 
3dpostVaccS 45.00 45.00 45.00 45.00 
4dpostVaccS 45.00 45.00 45.00 45.00 
5dpostVaccS 45.00 45.00 45.00 45.00 
preVaccW 34.81 36.72 45.00 36.90 
1dpostVaccW 45.00 37.06   
2dpostVaccW 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 38.75 45.00 45.00 
5dpostVaccW 45.00  45.00 45.00 
H: Horse number; CT: Cyclic Treshold; preVaccS: pre summer vaccination; dpostVaccS: days post summer 
vaccination; preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 20 (Group C): Longitudinal EHV-1 nasal shedding in horses with no EHV-1 
vacination history which received a basic immunization in summer (2 doses 4 weeks apart) followed by a 
booster vaccine 6 months later, in winter (n = 6) 
 H7 H8 H9 H10 H11 H21 
preVaccBI1    38.42  Missing sample 
1dpostVaccBI1 45.00 45.00 45.00 45.00 45.00 Missing sample 
2dpostVaccBI1 45.00 45.00 45.00 45.00 45.00 Missing sample 
3dpostVaccBI1 45.00  45.00 37.85 45.00 Missing sample 
4dpostVaccBI1 45.00  45.00 45.00 45.00 Missing sample 
5dpostVaccBI1 45.00  45.00 45.00 45.00 Missing sample 
preVaccBI2 28.98 32.93 33.93 34.11 34.54 Missing sample 
1dpostVaccBI2 45.00 45.00 45.00 45.00 45.00 Missing sample 
2dpostVaccBI2 45.00 45.00 45.00 45.00 36.34 Missing sample 
3dpostVaccBI2 45.00 45.00 45.00 45.00 45.00 Missing sample 
4dpostVaccBI2 45.00  45.00 45.00 45.00 Missing sample 
5dpostVaccBI2 43.70 35.82 45.00 45.00 45.00 Missing sample 
preVaccW 45.00 27.56 31.95 27.92 31.80 45.00 
1dpostVaccW 45.00 45.00 45.00 45.00 43.19 45.00 
2dpostVaccW 09.91 36.29 36.10 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 45.00 36.90 36.78 45.00 45.00 
5dpostVaccW 45.00 45.00 45.00 45.00 45.00 45.00 
H: Horse number; CT: Cyclic Treshold; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccBI1: pre vaccination with the first dose of the basic immunization; preVacBI2: pre vaccination with the 
second dose of the basic immunization; dpostVaccBI2: days after the second dose of the basic immunization; 
preVaccW: pre winter vaccination; mpostVaccW: days post winter vaccination; 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 21: Longitudinal EHV-1 nasal shedding in control Group D (n = 5) 
 H1 H2 H3 H4 H6 
preVaccS 45.00 45.00 45.00 45.00 45.00 
1dpostVaccS 45.00 45.00 45.00 45.00 45.00 
2dpostVaccS 45.00 45.00 45.00 45.00 45.00 
3dpostVaccS 45.00 45.00 45.00 45.00 45.00 
4dpostVaccS 45.00 45.00 45.00 45.00 45.00 
5dpostVaccS 45.00 45.00 45.00 45.00 45.00 
preVaccW 45.00 45.00 45.00 36.72 45.00 
1dpostVaccW 45.00 45.00 45.00 45.00 45.00 
2dpostVaccW 45.00 45.00 45.00 36.31 45.00 
3dpostVaccW 35.83 45.00 45.00 45.00 45.00 











H: Horse number; CT: Cyclic Treshold; preVaccS: pre summer vaccination; dpostVaccS: days post summer 
vaccination; preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; No vaccination 
history and no vaccination as part of the study; natural exposure due to an outbreak occurred mid-terms between 
summer and winter sampling period; 




CT-Values corresponding to Fig. 22 (Group A-C): EHV-4 nasal shedding over 5 days in horses vaccinated 
against EHV-1/4 with different protocols (n = 15) 
 H7 H8 H9 H10 H11 H12 H13 H14 




































preVaccBI2 26.47 31.23 29.78 30.84 31.97    
1dpostVaccBI2 45.00 45.00 45.00 45.00 45.00    
2dpostVaccBI2 45.00 45.00 45.00 45.00 45.00    
3dpostVaccBI2 45.00 45.00 45.00 45.00 45.00    
4dpostVaccBI2 45.00  45.00 45.00 45.00    
5dpostVaccBI2 35.85 35.21 45.00 45.00 36.21    
preVaccW 45.00 24.98 29.27 24.58 29.30 33.67 43.90 45.00 
1dpostVaccW 45.00 37.83 45.00 34.92 33.67 45.00 45.00 45.00 
2dpostVaccW 45.00 33.76 36.36 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 34.91 45.00 45.00 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 35.61 45.00 34.93 35.82 45.00 40.53 45.00 





 H16 H17 H18 H19 H21 H22 H23 
preVaccS/preVaccBI1 32.76 35.87 31.94  Missing 
sample 
44.75 31.23 
1dpostVaccS/1dpostVaccBI1 45.00 45.00  45.00 Missing 
sample 
45.00 45.00 
2dpostVaccS/2dpostVaccBI1 45.00 45.00  45.00 Missing 
sample 
45.00 45.00 
3dpostVaccS/3dpostVaccBI1 45.00 45.00 45.00 45.00 Missing 
sample 
45.00 45.00 
4dpostVaccS/4dpostVaccBI1 45.00 35.53 45.00 36.54 Missing 
sample 
45.00 45.00 
5dpostVaccS/5dpostVaccBI1 45.00 45.00 45.00 45.00 Missing 
sample 
45.00 45.00 
preVaccBI2     Missing 
sample 
  
1dpostVaccBI2     Missing 
sample 
  
2dpostVaccBI2     Missing 
sample 
  
3dpostVaccBI2     Missing 
sample 
  
4dpostVaccBI2     Missing 
sample 
  
5dpostVaccBI2     Missing 
sample 
  
preVaccW 32.63 33.37 45.00 33.41 45.00 38.74 45.00 
1dpostVaccW 45.00 45.00  45.00 45.00 45.00 45.00 
2dpostVaccW 45.00 36.14 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 34.87 37.92 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 32.27 45.00 45.00 45.00 45.00 45.00 
5dpostVaccW 45.00  45.00 45.00 45.00 45.00 45.00 
H: Horse number; CT: Cyclic Treshold; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccS: pre summer vaccination; dpostVaccS: days post summer vaccination; 
preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
preVaccBI1: pre vaccination with the first dose of the basic immunization (Group C only); 
preVacBI2: pre vaccination with the second dose of the basic immunization (Group C only); 
dpostVaccBI1: days after the first dose of the basic immunization (Group C only) 
dpostVaccBI2: days after the second dose of the basic immunization (Group C only) 
Group A (H12, 13, 14, 22, 23) BI >4 years ago, q6months booster which was continued throughout the study; 
Group B (H16, 17, 18, 19), no vaccination history, vaccinated two times, six months apart without prior BI; 
Group C (H7, 8, 9, 10, 11, 21) no vaccination history, BI in summer followed by a booster after six months 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 23 (Group A): Longitudinal EHV-4 nasal shedding in horses vaccinated 
against EHV-4 with a basic immunization >4 years ago with regular boosters every 6 months including summer 
and winter during the study (n = 5) 











































preVaccW 33.67 43.90 45.00 38.74 45.00 
1dpostVaccW 45.00 45.00 45.00 45.00 45.00 
2dpostVaccW 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 40.53 45.00 45.00 45.00 
5dpostVaccW 45.00 45.00 45.00 45.00 45.00 
H: Horse number; CT: Cyclic Treshold; preVaccS: pre summer vaccination; dpostVaccS: days post summer 
vaccination; preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 24 (Group B): Longitudinal EHV-4 nasal shedding in horses with no 
vaccination history against EHV-4 and vaccinated twice 6 months apart in summer and winter during the study 
(n = 4) 
 H16 H17 H18 H19 
preVaccS 32.76 35.87 31.94  
1dpostVaccS 45.00 45.00  45.00 
2dpostVaccS 45.00 45.00  45.00 
3dpostVaccS 45.00 45.00 45.00 45.00 
4dpostVaccS 45.00 35.53 45.00 36.54 
5dpostVaccS 45.00 45.00 45.00 45.00 
preVaccW 32.63 33.37 45.00 33.41 
1dpostVaccW 45.00 45.00  45.00 
2dpostVaccW 45.00 36.14 45.00 45.00 
3dpostVaccW 45.00 34.87 37.92 45.00 
4dpostVaccW 45.00 32.27 45.00 45.00 
5dpostVaccW 45.00  45.00 45.00 
H: Horse number; CT: Cyclic Treshold; preVaccS: pre summer vaccination; dpostVaccS: days post summer 
vaccination; preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 25 (Group C): Longitudinal EHV-4 nasal shedding in horses with no EHV-4 
vacination history which received a basic immunization in summer (2 doses 4 weeks apart) followed by a 
booster vaccine 6 months later, in winter (n = 6) 
 H7 H8 H9 H10 H11 H21 
preVaccBI1    34.14  Missing sample 
1dpostVaccBI1 45.00 45.00 45.00 45.00 45.00 Missing sample 
2dpostVaccBI1 45.00 45.00 45.00 45.00  Missing sample 
3dpostVaccBI1 45.00  45.00 45.00 45.00 Missing sample 
4dpostVaccBI1 45.00  45.00 45.00 45.00 Missing sample 
5dpostVaccBI1 45.00 45.00 45.00 45.00 45.00 Missing sample 
preVaccBI2 26.47 31.23 29.78 30.84 31.97 Missing sample 
1dpostVaccBI2 45.00 45.00 45.00 45.00 45.00 Missing sample 
2dpostVaccBI2 45.00 45.00 45.00 45.00 45.00 Missing sample 
3dpostVaccBI2 45.00 45.00 45.00 45.00 45.00 Missing sample 
4dpostVaccBI2 45.00  45.00 45.00 45.00 Missing sample 
5dpostVaccBI2 35.85 35.21 45.00 45.00 36.21 Missing sample 
preVaccW 45.00 24.98 29.27 24.58 29.30 45.00 
1dpostVaccW 45.00 37.83 45.00 34.92 33.67 45.00 
2dpostVaccW 45.00 33.76 36.36 45.00 45.00 45.00 
3dpostVaccW 45.00 34.91 45.00 45.00 45.00 45.00 
4dpostVaccW 45.00 35.61 45.00 34.93 35.82 45.00 
5dpostVaccW 45.00 45.00 45.00 45.00 45.00 45.00 
H: Horse number; CT: Cyclic Treshold; BI: Basic immunization consisting of two doses given 4 weeks apart 
preVaccBI1: pre vaccination with the first dose of the basic immunization; preVacBI2: pre vaccination with the 
second dose of the basic immunization; dpostVaccBI2: days after the second dose of the basic immunization; 
preVaccW: pre winter vaccination; mpostVaccW: days post winter vaccination; 
Timepoints before each vaccination administration are written in italics 




CT-Values corresponding to Fig. 26: Longitudinal EHV-4 nasal shedding in control Group D (n = 5) 
 H1 H2 H3 H4 H6 
preVaccS 45.00 45.00 45.00 45.00 45.00 
1dpostVaccS 45.00 45.00 45.00 45.00 45.00 
2dpostVaccS 45.00 45.00 34.99 45.00 45.00 
3dpostVaccS 45.00 45.00 45.00 45.00 45.00 
4dpostVaccS 45.00 45.00 45.00 45.00 45.00 
5dpostVaccS 45.00 45.00 45.00 45.00 45.00 
preVaccW 45.00 45.00 45.00 45.00 45.00 
1dpostVaccW 45.00 45.00 45.00 45.00 45.00 
2dpostVaccW 45.00 45.00 45.00 45.00 45.00 
3dpostVaccW 45.00 45.00 45.00 45.00 45.00 











H: Horse number; CT: Cyclic Treshold; preVaccS: pre summer vaccination; dpostVaccS: days post summer 
vaccination; preVaccW: pre winter vaccination; dpostVaccW: days post winter vaccination; No vaccination 
history and no vaccination as part of the study; natural exposure due to an outbreak occurred mid-terms between 
summer and winter sampling period; 
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